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A B S T R A C T 
Bronchial asthma is a common inflammatory disorder which is characterized 
by hyperactivity, hypersecretion and bronchoconstriction. One of the pro-
inflammatory mediators released by the bronchi is cysteinyl leukotrienes (CysLTs). 
They are lipid mediators derived from arachidonic acid by the 5-lipoxygenase (5-LO) 
pathway and play critical roles in the pathogenesis of asthma. CysLTs exert their 
biological effects via specific G-protein-coupled receptors. To date, there are two 
cloned human CysLT receptor subtypes, namely CysLTi and CysLT]. Specific 
CysLTi receptor antagonists, such as montelukast, pranlukast and zafirlukast are 
available for clinical use in the treatment of asthma. Recently, a crosstalk between 
CysLTi receptor and P2Y6 receptor is being delineated. P2Y6 is a member of P2Y 
receptor family, which is expressed in apical and/or basolateral membranes of 
virtually all polarized epithelia to control the transport of fluid and electrolytes. In the 
airway, CI" secretion and Na+ reabsorption can be modulated by activation of multiple 
P2Y receptors, which couple to the phospholipase C (PLC) and calcium signalling 
pathway. The aim of this project is to examine the effect of specific CysLTi receptor 
antagonists on nucleotides acting on P2Y6 receptor in a human bronchial epithelial 
cell line (16HBE14o-) and to investigate the possible signal transduction pathway the 
antagonists may act through. 
The Western blot analysis of 16HBE14o- cells confirmed that CysLTi and 
P2Y6 receptors were expressed in this cell line. The functional study employed two 
techniques that respectively measure basal short-circuit current (Isc) and intracellular 
calcium concentration ( [Ca "^ ] i ) in the epithelia. Cells were grown on Transwell-COL 
membranes and glass coverslips for 9-10 days using standard techniques. The 
confluent 16HBE14o- cell monolayers were clamped in conventional an Ussing 
chamber and incubated in normal Krebs-Henseleit (KH) solution. The electrogenic 
ion transport activities were measured using short-circuit current (Isc) technique. Cell 
grown on glass coverslips were loaded with the calcium-sensitive fluorescent dye 
Fura-2/AM. An increase in [Ca"^]i will cause an increase in the Fura-2 fluorescence 
V 
ratio and this allows changes in [Ca~ ]^i to be monitored using calcium imaging 
technique. 
Recently, our laboratory finding suggests that the P2Y6 receptor agonist, UDP, 
could stimulate both and cAMP-dependent chloride ion secretion in the 
16HBE140- epithelia. In general, all three specific CysLTi receptor antagonists 
inhibited the UDP-evoked Isc, and hence the chloride secretion across the epithelia. 
The elevation of [Ca" *^]； is caused by an increased production of inositol trisphosphate 
(IP3), which is triggered by the coupling of P2Y6 receptors with PLC upon addition of 
UDP. Data showed that of the three specific CysLTi receptor antagonists 
(montelukast, pranluakast and zafirlukast), only montelukast inhibited the UDP-
evoked [Ca~ ]^i increase in a concentration dependent manner. Application of U73122 
(a PLC inhibitor) or Xestospongin C (an IP3 receptor blocker) inhibited the UDP-
induced [Ca"^]i increase. Co-incubation of either U73122 or Xestospongin C with 
montelukast did not cause additional inhibition to the UDP-induced [Ca~^]i increase. 
Thus, it is likely that montelukast interferes with the -dependent pathway at the 
receptor level, possibly by blocking the receptor and hence the activation of PLC and 
the production of IP3. Besides, 16HBE14o- epithelia express at least four subtypes of 
P2Y receptor, namely P2Y,, P2Y2, P2Y4 and P2Y6. Montelukast had no inhibitory 
effect on the P2Yi, P2Y2 or P2Y4 agonist-induced [Ca"^]i increase, suggesting that it 
selectively inhibits P2Y6 receptor pathway. The data, therefore, further confirms the 
inhibitory action of montelukast on the UDP-induced [Ca"^]i increase may lie at the 
receptor level. 
In 16HBE140- cells, stimulation of P2Y6 receptors not only causes an increase 
in [ C a ' ^ ] i but also cAMP production, which in turn could activate protein kinase A 
(PKA) and an exchange protein directly activated by cAMP (Epac). In the presence of 
8-Br-cAMP (a cAMP analogue), the UDP-induced Isc was potentiated, which could be 
reduced by pranlukast. However, montelukast failed to inhibit the potentiation of the 
UDP-induced Isc increase caused by 8-Br-cAMP. In other words, cAMP signalling 
was interfered by pranlukast and zafirlukast, but not by montelukast. 8-Br-cAMP is a 
general cAMP level elevator, which cannot distinguish between its two downstream 
targets, PKA and Epac. 8-CPT-2'-0-Me-cAMP (a specific activator of Epac) was 
thus employed to potentiate the UDP-evoked Isc. Pranlukast inhibited the UDP-
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evoked Uc potentiated by Epac while montelukast and zafirlukast had no such effect. 
Sp-6-Phe-cAMP, was also employed to be an Epac negative control. Only zafirlukast 
inhibited the potentiated UDP-induced Isc. It indicates that pranluakst may inhibit the 
cAMP-dependent pathway by acting through Epac, whilst zafirlukast acting through 
PKA. Monteluakst, on the other hand, does not exert similar inhibitory action. 
In summary, our data demonstrates that the three specific CysLTi receptor 
antagonists have different pharmacological actions against P2Y6 receptor-mediated 
signalling pathway in 16HBE14o- cells. Although all antagonists inhibited the UDP-
evoked Isc increase, only montelukast inhibited signalling by blocking the P2Y6 
receptor while pranlukast inhibited the cAMP signalling mediated by Epac. 
Zafirlukast inhibited UDP-evoked Isc increase but the underlying regulatory 
pathway(s) remains to be elucidated. The data showed that these three specific 
CysLT) receptor antagonists are not as highly specific as they were thought to be, and 
this may provide implications for the clinical use of these compounds in asthma or 




收縮。其中在支氣管釋放的一個親炎症介質是半胱氧酸白三稀 (CysLTs ) � 
他們是來自脂質介質的花生四炼酸5脂氧合摘（5 -L0 )路徑，這種路徑在哮 
喘的發病機制上發揮關鍵的作用。CysLTs通過個別的G蛋白偶聯受體發揮其 


































刺激CAMP生產，這又可以激活蛋白激酶A ( PKA )和交換蛋白直接激活腺 






酸。因此，我們採用了交換蛋白直接激活腺苷酸的特定激活劑 (8 -CPT-2’ -0 -
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1.1 Regulation of human airway surface liquid 
Human airway is lined by ciliated epithelium, which is covered by airway 
surface liquid (ASL). ASL is divided into two layers, the periciliary liquid layer (PCL) 
and the mucous layer lying above PCL (Lucas & Douglas, 1994). Airway mucus 
clearance is maintained by proper thickness and composition of the ASL (Matsui et 
al., 1998; Tarran et aL, 2001). To facilitate the ciliary beating, the depth of PCL is 
regulated to a level that approximates the length of outstretched cilia. It ensures 
mucous to be removed efficiently. 
In order to maintain a proper volume and composition of PCL, it is crucial to 
keep a balance between absorption and secretion of ions and fluid in airway epithelia. 
The active and passive transport of ion and water across epithelial cells is regulated by 
a series of ion channels and transporters located at apical or basolateral membrane of 
the cells. Any defect in ion transport functions of airway cells can affect PCL. The 
lack or insufficient amount of PCL impairs the beating action of cilia, and thus 
hampers the mucociliary clearance (Pilewski & Frizzell，1999). As a result, the mucus 
accumulated on airway surface leads to airway obstruction and bacterial infection 
(Matsui et al., 1998; Tarran et al., 2001), which may trigger the release of 
inflammatory mediators and cause inflammatory implications such as asthma. 
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1.2 Cysteinyl ieukotrienes in asthma 
Asthma is a chronic inflammatory disorder characterized by a series of 
structural changes of bronchial airways, including bronchoconstriction, mucus 
secretion, airway edema. These symptoms are caused by activation of inflammatory 
cells and thus an increased production of inflammatory mediators. One of the key 
mediators is cyteinyl Ieukotrienes (CysLTs) (Nicosia et al, 2001). 
The CysLTs (i.e. LTC4, LTD4 and LTE4) are synthesized by macrophages, 
eosinophils, mast cells and basophils (Busse & Kraft, 2005). They are shown to 
mediate various pro-inflammatory effects in respiratory diseases, such as asthma 
(Drazen, 2003) and allergic rhinitis (Mygind et al., 2000); but also have been 
implicated in other diseases, such as cardiovascular (Folco et al., 2000), 
gastrointestinal, skin and immune disorders (Sampson et al., 2003). The cellular 
source and their effects are summarized in Fig. 1.2.1. 
They are a family of potent bioactive lipids which are derived de novo from 
arachidonic acid, a fatty acid found in all cell membranes. Arachidonic acid is 
converted to 5-hydroperoxy-eicosatetraenoic acid (5-HPETE) and enters the 5-
lipoxygenase (5-LO) pathway, in which 5-HPETE is subsequently converted to LTA4 
and LTB4 by the enzymes 5-LO and LTA4H respectively (Samuelsson, 1983; Reid et 
al., 1990). LTA4 would then be catalyzed by LTC4 synthase to form LTC4, which is 
converted to LTD4 and then to LTE4 by other enzymes. LTE4 is eventually excreted in 
urine without further chemical change (Lee et al., 1983; Lam et al.’ 1994). These 
CysLTs then act on various types of CysLT receptors. LTB4, on the other hand, acts 
on LTBRl, LTBR2 or PPARa. The synthesis of CysLTs is summarized in Fig. 1.2.2. 
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Figure 1.2.1 Cellular sources of CysLTs and their effects on airway and inflammatory 
cells. (Adapted from Nicosia et al” 2001) 
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Figure 1.2.2 The synthesis of CysLTs (Adapted from Duroudier et al., 2009). 5-LO, 
5-Iipoxygenase; aa, arachidonic acid; CYSLTR, cysteinyl leukotriene receptor; DP, 
dipeptidase; FLAP, 5-lipoxygenase activating protein; y-GT, y-glutamyl transpeptides; 
LTBR, leukotriene B4 receptor; LTA4, LTB4, LTC4, LTD4, LTE4, leukotriene A4, B4, 
C4, D4, E4； LTA4H, LTA4 hydrolase; LTC4S, LTC4 synthase; LIRA, leukotriene 
receptor antagonists; LTSI, leukotriene synthesis inhibitor; MRPl, multi-drug 
resistant protein 1; PLA2, phospholipase A2； PPARa，peroxisome proliferator 
activated receptor alpha. 
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1.3 Cysteinyl leukotriene receptors in epithelial cells 
CysLTs trigger inflammatory processes by interacting with their cell surface 
specific receptors, which belong to the rhodopsin family of the G protein-coupled 
receptor (GPCR) gene superfamily (Evans, 2002). Molecular study has revealed that 
they are seven trans-membrane spanning proteins. Pharmacological studies have 
confirmed that there are three classes of CysLT receptors, namely CysLTi, CysLT� 
and the newly recognized CysLTs (Brink et al., 2003; Evans et al, 2007), which have 
been found and cloned in human (Sarau et al.’ 1999; Heise et al., 2000). CysLTi and 
CysL丁2 mRNA are found in cells related to asthma or allergy such as monocytes and 
eosinophils, but the CysLT: mRNA found is much less in quantity (Lotzer et al., 
2003). Both receptors are expressed in the human body, such as lung, spleen, and 
heart (Kanaoka et al” 2004). In particular, several studies showed that CysLTi and 
CysL丁2 receptors are expressed in bronchial epithelial cells (Brink et al., 2003; 
Profita et al” 2008). CysLT3 receptor, on the other hand, has not been found to have 
pathological or physiological role (Ciana et al” 2006). 
Studies showed that CysLTi and CysLT�receptors have different functions. 
Comparing to CysLT:，CysLTi receptor has a more extensive effect on bioactivities 
of various aspects, such as inflammation, immune response, vascular and smooth 
muscle responses and cell repair (Kanaoka et aL, 2004). Fig. 1.3.1 summarizes the 
bioactivities involved in these two receptors. 
The CysLTs receptors have different affinities to LTC4, LTD4 and LTE4. 
CysLT, binds preferentially to LTC4, with 200-fold less affinity to LTD4 and LTE4； 
whereas CysLT�shows a low, but equal, affinity for LTC4 and LTD4, and has much 
less affinity to LTE4 (Lynch et al, 1999). Upon stimulation of the endogenous ligands, 
the receptors would activate intracellular signalling pathways, which include 
phospholipase C, and Ca^^- dependent tyrosine kinases (Capra et al., 2006). 
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Figure 1.3.1 Bioactivities of the CysLTs and their receptors. (Adapted from Kanaoka 
et al., 2004) 
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1.4 Particular interest on CysLTi receptor 
Although CysLTi and CysLTa mRNA are found in cells related to asthma or 
allergy such as monocytes and eosinophils, the CysLT�mRNA found is much less in 
quantity (Lotzer et al., 2003). Recently, it was also demonstrated that CysLTi mRNA 
was upregulated in asthmatic bronchial mucosa (Zhu et al., 2005). Thus, it is 
generally agreed that most of the actions of the CysLTs are mediated by the CysLTi 
receptor. For example, blockade of CysLTi receptors in human mast cells prevents 
CysLT-mediated phosphorylation of ERK, even though the cells express both 
receptors (Mellor et al., 2003). Conversely, due to the lack of specific antagonists, 
less is known about the CysLT� receptor, and the data present in the literature are 
quite controversial. 
The molecular structure of CysLTi has been identified. It possesses four 
potential N-glycosylation sites, in which one in the extracellular N-tail, two in the 
second and one in the third extracellular loop. Besides, there are many potential 
protein kinase A and C phosphylation sites mostly located in the third intracellular 
loop and carboxyl terminal (Lynch et al., 1999). Fig. 1.4.1 shows the putative 
membrane topology of CysLTi receptor. 
Chan et al. demonstrated that after binding of LTD4, one of the CysLTi 
receptor ligands, to CysLTi receptor, the GPCR would interact and activate 
heterotrimeric G-proteins. There are four main classes of heterotrimeric G-proteins 
which are classified by their a-subunits. They are designated as Gs, Gj, Gq/n and G12-
13. Without activation, the a-subunits of the heterotrimer bind to GDP and are 
associated with a Gpy dimer. Activated by the ligand, GPCR interacts with the 
heterotrimeric G-proteins and causes the release of GDP. As a result, the a-subunit 
and the Gpy dimer dissociate, and then can interact with a variety of downstream 
effectors, such as lipases, protein kinases, and ion channels. The LTD4-CysLTi 
activation leads to several responses. It is well known that CysLTi receptor signals 
through elevation of intracellular calcium (Chan et al., 1994). Some studies showed 
that it induced intracellular calcium mobilization in human intestinal epithelial cells 
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(GrOnroos et al, 1996), and human monocytes, mediating through PLC (Deshpande et 
ah 2007). 
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Figure 1.4.1 Putative membrane topology of human CysLTi receptor identified in the 
Tristan de Cunha population (Thompson et al, 2007). G300S and I206S are the single 
amino acid variants. 
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1.5 Cysteinyl leukotrienes receptor antagonists 
Currently, there are several CysLTi receptor antagonists. Three of them are 
commonly prescribed to human patients as preventive mediation, namely montelukast, 
pranlukast and zafirlukast. These three antagonists are from distinct chemical classes 
Jones et al.’ 1989; Salvi et ai, 2001). Among the three, montelukast (Singulair®) is 
the most potent one, which is now used as a preventative drug for asthma and allergic 
rhinitis in adults and children (Jarvis et al, 2000). Pranlukast (Onon®, Azlaire®) is 
only available in Japan and South America, and acts as a prophylactic treatment of 
chronic bronchial asthma in pediatric and adult patients (Keam et al, 2003). 
Zafirlukast (Accolate®) is also used to treat chronic asthma (Krell et al” 1990). All of 
them are proven to have an alleviating effect on the symptoms of airway disease, 
especially bronchial asthma and allergic rhinitis (Suissa et al., 1997; Capra et al., 
2006; Riccioni et al., 2007). These three antagonists block the binding of CysLTs to 
their receptors and thus prevent the signalling cascade induced by CysLTs. (Krell et 
al., 1990) 
Currently CysLT� receptor has no specific antagonists. The only available 
antagonist for CysLT� receptor is BAY u9773, which is a 'dual' antagonist that has 
activity at both CysLTi and CysLT� receptors (Labat et al, 1992; Gardiner et al., 
1994). BAY u9773 antagonizes in vitro allergen-induced contraction of human 
bronchi (Labat et al.’ 1992). However, data in vivo is not yet available. 
Recently, it has been reported that CysLTi receptor antagonists functionally 
interact with the sigalling pathway of purinergic 2Y receptors (Mamedova et al., 2005; 
Capra et al., 2005). For example, Mamedova et al. showed that montelukast and 
pranlukast inhibit both the P2Y agonist-induced intracellular calcium mobilization 
and activation of phospholipase C (Mamedova et al., 2005). A study by Jiang et al. 
also found that CysLTi and P2Y6 receptors bind to their own endogenous ligands and 
reciprocally amplify each other's function in mast cells (Jiang et al” 2009). These 
bring attention to the possible interaction between these two receptor families, which 
both belong to the G-protein coupled receptor family. 
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1.6 Purinergic receptors in epithelial cells 
Similar to CysLT receptors, purinergic receptors are also G-protein coupled 
receptors. In particular, it was found that CysLT receptors are phylogenetically related 
to the purine P2Y receptors (Costanzi et al, 2004). Notably, purines are also known to 
be involved in inflammatory responses, e.g. the recruitment of monocytes and 
neutrophils to the injury site (Kunapuli & Daniel, 1998). The structural and functional 
similarities between these two receptors raise the awareness of the possible 
communication between them. Recently, it has been reported that crosstalk between 
purine and leukotriene systems exists (Mamedova et al” 2005; Capra et al., 2005; 
Jiang et al., 2009). 
Purinergic receptors are ubiquitous transmembrane receptors that are 
subdivided into two major classes, PI and P2 receptors. PI receptors are mainly 
activated by adenosine while P2 receptors are activated by extracellular nucleotides, 
such as ATP, UDP, UTP and ADP. These receptors stimulate various intracellular 
signalling pathways, including those related to inflammation (Di Virgilio et al., 2008). 
PI receptors have four subtypes, namely Ai, A2A, A2B，and A3. They are from 
a family of G-protein-coupled receptors which are activated by nucleotides. All of 
them have their unique roles in epithelial tissue cells (Buchemier & Linden，2004). 
P2 receptors are divided into two subtypes, P2Y and P2X receptors. The 
former one belongs to the GPCR superfamily (Bhagwat & Williams, 1997). P2Y and 
P2X receptors are found to possess multiple isoforms. There are eight P2Y receptors 
subtypes (P2Yi, P2Y2, P2Y4, P2Y6, P2Yn, P2Yi2, P2Y,3 and P2Y,4) and eight P2X 
receptor subtypes (P2X1.7 and P2XM) (Buchemier & Linden, 2004). As mentioned 
above, P2Y receptors are activated by extracellular nucleotides, such as ATP, UDP, 
UDP, and ADP. The P2Y subtypes respond differentially and selectively to specific 
diphosphate or triphosphate nucleotides (Fredholm et al, 1994; Harden et al, 1997). 
Their preferences for naturally occurring ligands are summarized in Table 1.6.1 (King 
et al’ 2001 ； Communi et al’ 2001). 
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Receptors Preferred natural agonists 
P2Yi ADP > ATP “ 
P2Y2 UTP = ATP 
P2Y4 UTP » ATP 
P2Y6 UDP > UTP > ADP 
P2Y,i ATP 
" P ^ ADP > ATP 
P2Y,3 ADP > ATP 
P2Yi4 UDP-glucose > UDP-galactose > UDP-N-acetylglucosamine 
Table 1.6.1 Natural ligands for P2Y receptors (Bucheimer & Linden, 2004) 
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1.7 P2Y receptors in epithelial cells 
Epithelial cells are the lining of internal organs, such as lung and 
gastrointestinal tract, and act as a barrier between the underlying cells and the external 
environment. The intracellular connection in the epithelia is maintained by tight 
junctions, which governs the paracellular permeability of the epithelia to regulate the 
flux of ions or fluid in paracellular space. Besides, tight junction also contributes by 
dividing the cell membrane into two structurally and functionally distinct domains in 
polarized cells. Cell surface above tight junction is named as apical surface while that 
below tight junction is named as basolateral surface (Yeaman et al” 1999). The 
differential expression of various receptor proteins between these two surfaces 
enables the cells to precisely regulate different cellular activities. 
Studies on the P2 receptors provide a deeper characterization of these 
receptors on airway epithelia. It was discovered that airway epithelia dominantly 
expresses P2 receptors (Mason et al., 1991). It was also demonstrated that P2 
receptors regulate ion transport in airway epithelium with NaCl secretion activation 
(Inglis et al., 1999; Homolya et al., 1999) and sodium ion reabsorption inhibition 
(Inglis et al” 1999; Mall et al” 2000) involved in the process. 
P2 receptors have two major classes, P2Y and P2X receptors. It was shown 
that in airway epithelial cells, the predominantly expressed P2 receptors are P2Y 
receptors (Bucheimer & Linden，2004). In addition, comparing with P2X receptors, 
P2Y receptors are found to carry a more important role in airway epithelia (Paradise 
et al” 1995; Wilson et al., 1998). 
Currently, eight P2Y receptor subtypes are recognized: P2Yi, P2Y2, P2Y4, 
P2Y6, P2Yii, P2Yi2, P2Yi3, P2Yi4 receptors. These receptors are expressed in 
epithelial cells from various tissues (Cressman et al., 1999; Homolya et aL, 1999; 
Leipziger, 2003). According to structural, phylogenetic properties and signalling 
coupling, P2Y receptors are sub-divided into two subclasses: A (P2Y 1,2,4.6,11) and B 
(P2Yi2’i3,i4) subclasses. In A subclass, receptors are preferentially coupled to Gq or Gs 
proteins, thus mediating phospholipase C and adenylate cyclase (AC). While 
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receptors in B subclass are mainly linked through Gj activation to inhibit AC activity 
(ibidem). 
Extracellular nucleotides are required to activate these receptor subtypes, so as 
to initiate and regulate various cellular activities. Thus extracellular nucleotide action 
is of physiological significance. It serves as the major natural defense system of 
airways that protects cells from adverse environments (Lazarowski & Boucher, 2001; 
Leiziger, 2003). For example, inhalation of foreign particles triggers the release of 
nucleotides in the airway, and subsequently activates P2Y receptors and it eventually 
initiates mucociliary clearance (Lazarowski & Boucher, 2001). 
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1.8 Signaling pathways of P2Y receptors by nucleotide stimulation 
Extracellular nucleotides are released in response to the external stimulus. 
They exert their actions on epithelial cells by binding to P2Y receptors which in turn 
couple to multiple signal transduction pathways inside the cells. Stimulation of P2Y 
receptors lead to dual activation of both phospholipase C (PLC) and adenylate cyclase 
(AC) (Son et al.’ 2004). 
Upon stimulation of nucleotides, the heterotrimeric Gq protein-coupled P2Y 
receptors activate PLC, by which phosphatidylinositol 4,5-diphosphate (PIP2) is 
stimulated to general insositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 
diffuses into the cytosol and mobilizes the intracellular calcium store by binding to its 
specific receptor (Taylor & Richardson, 1991; Marshall & Taylor, 1993). Rise in 
intracellular calcium concentration activates Ca^'^-dependent CI" or K+ channels. 
Meanwhile, protein kinase C is activated by the accumulation of DAG in the 
cytoplasm. 
On the other hand, stimulation of P2Y receptors also activates AC, resulting in 
a rise in second messenger, adenosine-3',5'-cyclic monophosphate (cAMP) 
production. cAMP in turn activates classic protein kinase A (PKA) and a family of 
novel cAMP sensor protein, namely as exchange protein directly activated by cAMP 
(Epac) (Rooij et al, 1998). PKA stimulates the activity of cAMP-dependent CI" or K+ 
channels (Cowley & Linsdell, 2002; Son et al.，2004). Epac, On the other hand, is a 
recently discovered protein (Kawasaki et aL, 1998). Upon binding of cAMP to Epac, 
Epac is dis-inhibited and thus activates GTPase, thereby allowing replication-
associated proteins (Rap) to interact with and to stimulate effector signalling 
molecules. This receptor was found to activate signalling pathways that regulate 
several pivotal cellular processes, including cell adhesion, cell-cell junction, secretion 
and calcium handling (Cheng et al” 2008). The hypothesized scheme of the 
regulatory pathway of P2Y receptors are summarized in Fig. 1.8.1. 
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Figure 1.8.1 A: A hypothesized scheme of the coupling of apical and basolateral 
P2Y6 receptor to different downstream signaling pathways and effectors (Adapted 
from Wong et al.’ 2008). CaCC: calcium-activated chloride channel; CFTR: cystic 
fibrosis transmembrane conductance regulator. B: A diagram showing the 
interconnectivity between the Epac and PKA-signaling pathway (Adapted from Bos, 
2006). AC, adenylate cyclase; Epac, exchange protein directly activated by cAMP; Gs: 
stimulatory G-protein; GEF: guanine nucleotide exchange factor; GAPs: GTPase-
activating proteins; PDE: phosphodiesterase. 
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1.9 Particular interest in P2Y6 receptor 
P2Y receptor subtypes are expressed in many cell types, such as vascular 
tissues, epithelial cells and hematopoietic cells. Cell damage due to vascular injury or 
shear stress initiates the release of large amounts of extracellular nucleotides, which in 
turn mediates signalling pathways to re-regulate the cell environment. Among all P2Y 
receptor subtypes, P2Y6 receptor contributes specifically in the inflammatory 
processes (Cox et al., 2005; Grbic et aL, 2008). 
It was reported that human bronchial epithelial cells (Communi et al” 1999), 
lung epithelial cells (Khine et aL, 2006), human nasal epithelial cells (Kim et al” 
2004), and rat colonic epithelial cells (Kottgen et al., 2003) express P2Y6 receptors. 
Besides, P2Y6 receptors are founded to inducibly express in both mouse and human 
intestinal epithelium with inflammation (Grbic et al” 2008). The expression of the 
P2Y6 receptors increased in intestinal epithelial cells with inflammation (Grbic et al., 
2008). Taken together, P2Y6 receptors may be thus specialized to amplify the innate 
immune responses to inflammatory stimuli that induce release of P2Y6 specific ligand, 
UDP. 
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1.10 Relation between CysLTi receptor and P2Y receptor 
It is widely agreed that activation of a number of receptors does not merely 
lead to a direct effect on a particular signalling pathway. Rather, it may amplify or 
inhibit the responses initiated by other signals inside the cell or within the same tissue. 
This would increase the complexity of signalling and the adaptability of the cells to 
adverse changes (Selbie & Hill, 1998). 
GPCRs represent the largest group of receptors for hormones and 
neurotransmitter, and consist of more than 800 putative members (Fredriksson et al., 
2003). Upon stimulation of its ligand, GPCR is activated and induces conformational 
change and couples to the heterotrimeric G proteins. Meanwhile, it would also be 
desensitized, i.e. GPCR gradually loses its responsiveness to the agonist (Ferguson, 
2001). There are mainly two types of desensitization: homologous and heterologous 
(Chuang et al., 1996). Homologous desensitization is strictly agonist-dependent, i.e. 
only activated receptors desensitize. On the contrary, in heterologous desensitization, 
activation of one receptor can result in reduced response to activation of other 
receptors that are not activated by the agonist (Bunemann et al., 1999). 
Recently, various studies showed that cross-talk exists between CysLTi and 
P2Y6 receptors. CysLTi and P2Y receptors both belong to the superfamily of GPCRs. 
Their phylogenetic relation is shown in Fig. 1.10.1. It was reported that CysLTi 
receptors in human cord blood-derived mast cells respond to UDP, the specific ligand 
of P2Y6 receptors (Mellor et al” 2001). Jiang et al showed that P2Y6 receptors 
cooperate with CysLTi receptors to promote cell survival and chemokine generation 
in human mast cells (Jiang et al., 2009). Mamedova et al. also suggested that CysLTi 
receptor antagonists interact functionally with signalling pathways of P2Y receptors 
(Mamedova et al., 2005). 
In addition to rich evidence demonstrating the functional similarities between 
these receptor families, the structural similarity between CysLTi and P2Y receptors is 
proven. In a study with chimeric CysLTi/P2Y2 receptors, the chimera behaved as 
CysLTi receptor and the activation of the chimera was inhibited by CysLTi 
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antagonists (Gearing et al.’ 2003). A GenBank search for sequences homologous with 
CysLTi and CysLT: revealed that these receptors share 24.2% homology with P2Y 
receptor family, and in particular, with P2Y6 subtype (Fredriksson et al, 2003). Also, 
the distribution of P2Y6 receptors and CysLTi receptors overlap in many 
inflammatory cells, such as leukocytes, eosinophil, blood monocytes, and mast cells 
(Mamedova et al., 2005; Ballerini et al.’ 2005). In addition, as mentioned above, it 
has been confirmed that these two receptors are involved in inflammatory processes 
(Kanaoka et al., 2004; Cox et al” 2005; Grbic et al” 2008). In short, based on the 
functional and structural similiarities between these two receptors, it is possible that 
they may cross-regulate and thus allow fine adjustment of inflammatory processes 
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Figure 1.10.1 Phylogenetic relationship between CysLT receptors and the members 
of the purine receptor cluster of the Rhodopsin group of GPCRs. (Adapted from 
Fredriksson et al, 2003) 
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1.11 The properties of 16HBE14o- cell line 
16HBE140- cell line has been immortalized from the human bronchial 
epithelial cell (Cozen et al” 1994). It can be easily maintained with high 
reproducibility. 16HBE14o- cells retain differentiated morphology and function of 
normal human epithelia form polarized monolayers that are comparable with 
bronchial epithelial in vivo (Salvi et al., 1999). Immunofluorescence staining and 
electron microscopy demonstrated that cell layers form well-defined tight, adherens, 
and gap junctions, and well-organized actin filaments (Ehrhardt et al., 2002). The 
presence of tight junctions indicated that directional ion transport property is retained 
in 16HBE140- cells (Welsh & Liedtke, 1986; Rechkemmer, 1988). 
Our lab and other studies demonstrated that 16HBE14o- cells express multiple 
P2Y receptors (Bumstock et al., 2006; Wong et al., 2009) and the expression ofP2Yi, 
P2Y2, P2Y4, and P2Y6 receptor subtypes have been characterized in this cell line 
(Communi et al” 1999). In addition, CysLT receptors are also present and can be 
activated in this cell line (Profita et al.’ 2008). Taken together, these properties allow 
the study of the interaction of CysLTi receptor antagonists on P2Y receptor-mediated 
signalling pathway and the ion transport process involved. 
16HBE140- cells were grown as polarized epithelia on permeable Transwell-
COL membrane supports and circular cover glass slips in medium-covered condition. 
Studies showed that epithelial cells cultured under such condition can highly mimic in 
vivo cell morphology and allows the simulation of drug effects in the authentic 
environment (Salvi et al, 1999; Ehrhardt et al, 2002). 
Introduction 22 
1.12 Objectives of the present project 
As mentioned above, CysLT receptors are expressed in this cell line and 
plenty of studies on P2Y receptor subtypes have long been done on this cell line. Thus, 
16HBE14o- is a suitable model to investigate the relationship between these two 
receptor families. The aims of the present project are to: 
a) to examine the effect of specific CysLTi receptor antagonists on nucleotides 
acting on P2Y6 receptor in the human bronchial epithelial cell line 
(16HBE140-); and 
b) to investigate the possible signal transduction pathway the antagonists may act 
through. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Solutions and chemicals 
Normal Krebs-Henseleit solution (KH solution) contained (in mM): 2.56 CaCb, 
117 NaCl, 4.7 KCl, 1.2 MgCb, 1.2 KH2PO4, 24.8 NaHCOs, and 11.1 D-glucose. Reduced 
c r KH solution was prepared by 20 Ca-gluconate, 10 NaCl, 107 Na-gluconate, 4.7 K-
gluconate, 1.2 MgSCU, 1.2 KH2PO4, 24.8 NaHCOs, and 11.1 D-glucose. Ca^ "" free KH 
solution was prepared by removing CaCb from normal KH solution. The solutions were 
continuously bubbled with 95% O2 and 5% CO2 to maintain the pH at 7.4 during all 
experiments. 
UTP (uridine triphosphate), UDP (uridine diphosphate), and forskolin were from 
Sigma (St Louis, MO, USA). Before use, UDP (lOmM) was incubated for one hour at 
37°C in normal KH solution containing hexokinase (100 U/ml, Roche, Indianapolis, IN, 
USA) and 22 mM D-glucose to remove any contaminating nucleotide triphosphates. The 
resulting solution was then aliquoted and stored at -20°C (Nicholas et al.’ 1996). 
Montelukast (sodium salt), pranlukast, zafirlukast and xestospongin C were from 
Cayman Chemical (Mi, USA). 8-Br-cAMP-AM (8- Bromoadenosine- 3丨，5'- cyclic 
monophosphate, acetoxymethyl ester), Sp-6-Phe-cAMPs (N^- Phenyladenosine- 3', 5'-
cyclic monophosphorothioate, Sp-isomer), and 8-CPT-2' -0-Me-c AMP (8-(4-
chlorophenylthio)-2'-0-methyladenosine- 3’，5'- cyclic monophosphate) were from 
BioLog Life Science (Bremen, Germany). 
U73122 (1 -(6-( 17p-3 -methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-
pyrrole-2,5-dione) was from Biosource Int. (Camarillo, CA). 2-Me-S-ADP (2-
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(Methylthio)adenosine-5'-(trihydrogen diphosphate) trisodium salt) was from Tocris 
(Ellisville, MO, USA). Fura-2-AM (Fura-acetoxymethyl ester) and Pluronic acid F127 
were from Molecular probes (Eugene, OR, USA). 
UTP, UDP, 2-Me-S-ADP, forskolin, and hexokinase were dissolved in distilled 
water while all the other chemicals in dimethyl sulphoxide (DMSO). 
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2.2 Cell culture 
The human bronchial epithelial cell line, 16HBE14o-, used in the experiment was 
derived from surface epithelium of mainstream, second-generation bronchi. This 
continuous cell line was generated by transformation of normal bronchial epithelial cells 
obtained from a 1-year-old heart-lung transplant patient. (Cozens et al” 1994). 
16HBE14o- was maintained in Minimum Essential medium with Earle's salt 
supplemented with 10% (v/v) Fetal Bovine Serum, 1 % (v/v) L-glutamine, 100 U/ml 
penicillin, and 100 |ag/ml streptomycin. The cells were cultured on plastic flask coated 
with bovine collagen I purchased from BD Biosciences (Bedford, MA, USA) and were 
then incubated in humidified 95 % air-5 % CO2 at 37°C for seven days until the cells 
became confluent. Culture medium was changed every 3 days. Trypsinization was done 
to passage the cultured cells to new flask every 7 days. All of the cell culture reagents 
were purchased from Invitrogen (Grand Island, NY, USA). 
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2.3 Measurement of intracellular calcium concentration with fluorescent 
imaging 
2.3.1 Preparation of 16HBE14o- cells for fluorescent imaging 
16HBE140- cells were seeded onto circular microscopic cover glass slips (Fisher 
Scientific, USA) with diameter of 25 mm. The cover glass slips were sterilized with 95 % 
ethanol. The cover glass slips were placed inside a circular dish with fresh culture 
medium. For the first day of the culture，the amount of culture medium added was 
confined to the area of the cover glass slips for accurate seeding density (Fig. 2.3.1.1). On 
the next day, extra fresh culture medium was added to cover the dish. The seeding 
density was 5 X cells /ml. The 16HBE14o- cells reached confluency after 9 - 1 0 
days. 
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Figure 2.3.1.1 16HBE14o- cells seeded onto the microscopic cover glass slip for 
measurement of For the first day of the culture, the amount of culture medium 
added was confined to the area of the cover glass slips. On the next day, extra fresh 
culture medium was added to cover the dish. 
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2.3.2 Measurement of with fluorescent imaging 
16HBE140- cells grown on circular cover glass slips reached confluency after 9 -
10 days, and were ready for the measurement of intracellular calcium concentration 
([Ca2+]i) (Yue et al.’ 2004). The was measured by microspectrofluorometric 
technique. The fluorescence system is shown in Fig. 2.3.2.1 A. 
Cells were loaded with Ca^^-sensitive fluorescent dye, Fura-2-acetoxymethyl 
ester (Fura-2-AM), by incubation of 40 minutes in humidified 95 % air-5 % CO2 at 37°C, 
bathed in normal KH solution containing 3 jiM Fura-2-AM and 1.6 |xM pluronic F127. 
Pluronic F127 is a non-ionic surfactant polyol that helps to solubilize water-insoluble 
dyes (McFadzean & Brownlee, 1995). Meanwhile, 2.5 |iM probenecid in 0.5 M NaOH at 
pH 7.4 was added to speed up fluorescent dye loading and leads to a more homogeneous 
Fura-2 dye distribution. Probenecid is used to minimize the leakage of fluorescent dye by 
inhibiting organic cation extrusion system (Leipziger et al.’ 1997; McAlroy et al., 2000). 
The glass cover slips with dye-loaded epithelium were mounted in a perfusion 
chamber on the stage of an inverted microscope (Olympus Co., Tokyo, Japan). The cells 
were viewed with a x40 water immersion objective (Nikon Co., Tokyo, Japan). The 
experimental setup is illustrated in Fig. 2.3.2.1 B. was measured by exciting the 
cells at 340 and 380 nm UV light. The intensities of emissions from 340 nm and 380 nm 
excitations were named the Fura-2 fluorescent ratios (340/380 run), and were recorded by 
a cooled charge-coupled device (CCD) camera (Photometries, USA). Calcium images 
were obtained by MetaFluor fluorescence ratio imaging system (Universal Imaging 
Corporation, USA). 
The whole setup was stabilized with perfusion of normal KH solution gassed with 
95 0/0 air-5 % CO2 at around 37°C by a water jacket for 5 minutes before experiments. 
The normal KH solution was then changed to Ca^^ free KH solution. Drugs were applied 
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to the cells by perfusion system. The signals were digitized and recorded to computer 
hard disc. 
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Figure 2.3.1 A: Experimental setup of the fluorescence system. B: 16HBE14o-
monolayers were mounted in the perfusion chamber. 
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2.4 Measurement of short-circuit current (Isc) and transepithalial resistance with 
Ussing chamber 
2.4.1 Preparation of 16HBE14o- cells for Isc and transepithelial resistance 
measurement 
16HBE14o- cells were seeded onto collagen-coated Transwell-COL filter 
membranes (Costar, Cambridge, MA, USA) with pores of 0.4 |xm diameter (Wong & Ko, 
2002). Each filter was affixed to a silicon circular disc with a culture area of 0.2 cm^ (Fig. 
2.4.1.1 A). The filter was then coated with collagen and sterilized under ultra violet light 
for 45 min. After sterilization, the filter was placed in a six-well plate and covered with 
fresh culture medium. The seeding density was 3 X 10^ cells /ml. The 16HBE14o- cells 
reached confluency after 9 - 1 0 days, with transepithelial resistant greater than 100 
Q . cm2. 
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Figure 2.4.1.1 Preparation of the permeable support before cell seeding. A: The 
Transwell-COL filter was affixed to a silicon circular disc with a culture area of 0.2 cm^. 
B: The filter was coated with collagen before cell seeding. 
Materials and Methods 3 3 
2.4.2 Measurement of Isc and transepithelial resistance with Ussing chamber 
After 9 - 1 0 days, 16HBE14o- cells grown on Transwell-COL filter reached 
confluency and were mounted in a Ussing chamber as described previous (Wong & Ko， 
2002). The Ussing chamber was equipped with 2 sets of electrodes in connection with a 
voltage-current clamp amplifier (MC6-VC4; Physiologic Instruments, San Diego, CA, 
USA). The arrangement for the complete Ussing chamber setup with electrodes is shown 
in Fig. 2.4.2.1. The U-shaped tubing system was connected to the chamber and filled with 
10 ml normal KH solution on both sides of the monolayers. The bath solution was gassed 
by 95 % air-5 % CO2 and heated by a water jacket to around 37°C. It was reported that 
C r is at equilibrium at the apical cell membrane of the 16HBE14o-. Thus, the apical KH 
solution was changed to a KH solution with reduced CI" concentration (10 mM). The 
purpose was to apply a basolateral to apical CI" gradient across the epithelia so as to 
provide a favorable gradient for CI" exit. The formula of the reduced [CI"] solution was 
stated previous in section 2.1. 
After the cells stabilized, the potential differences across the monolayers were 
clamped at 0 mV. The current required to reduce the potential difference between the 
apical and basolateral bathing solutions to zero is known as short-circuit current (Isc). Isc 
was measured with the amplifier stated above and recorded with a chart recorder (Kipp & 
Zonen, Delft, The Netherlands). The transepithelial resistance of the epithelium was 
obtained by applying a constant voltage of 1 mV periodically. The resultant change in 
current was measured and the transepithelial resistance was calculated in accordance to 
Ohm's law. 
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Figure 2.4.1 Experimental setup for measurement of Isc. A: the 16HBE14o- monolayer 
filter was mounted between two halves of the Ussing chamber, which are connected with 
electrodes; B: the U-shaped tubing systems , connected to the Ussing chamber, was filled 
with bathing solutions gassed with 95 % air-5 % CO2. 
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2.5 Immunoblot analyses for CysLTi and P2Y6 receptors 
16HBE14o- monolayers were grown on 6-well plate for 9 to 10 days. The seeding 
cell density was 3 x 10^ cells per well. The cells were incubated in serum-free medium 
one day before experiment. The monolayers of 16HBE14o- cells were washed with cold 
phosphate-buffered saline at pH 7.4. The cells were harvested by cell scrapping and then 
transferred to lysis buffer containing p-glycerophosphate, sodium orthovanadate, 
proteinase inhibitor cocktail, okadaic acid and phenylmethylsulphonylfluoride. The 
supernatant were collected and stored at -70°C until use. 
The protein samples were pre-heated at 100°C for 10 minutes in 2X loading 
buffer and loaded onto 10 % sodium dodecyl sulphate-polyacrylamide gel for 
electrophoresis. Then, the protein samples were transferred to polyvinylidene difluoride 
membranes by semi-dry blotting. The membranes were blocked with 1% Bovine Serum 
Albumin (BSA) solution at room temperature for one hour. The membranes were washed 
in wash buffer (PBST) for 15 minutes at room temperature three times. CysLTi Receptor 
Polyclonal Antibody (Cayman Chemical, Ann Arbor, MI, USA) and P2Y6 Receptor 
Polyclonal Antibody (Alomone, Israel) were diluted at the ratio of 1:300 and 1:200 in 
PBST respectively. CysLTi Receptor Blocking Peptide (Cayman Chemical, Ann Arbor, 
MI, USA) and P2Y6 Receptor Blocking Peptide (Alomone, Israel) were mixed 
respectively with CysLTi Receptor Polyclonal Antibody and P2Y6 Receptor Polyclonal 
Antibody in a 1:1 (v/v) ratio. Subsequently, the membranes were incubated with the 
mixtures of CysLTi Receptor Polyclonal Antibody with CysLTi Receptor Blocking 
Peptide and P2Y6 Receptor Polyclonal Antibody with P2Y6 Receptor Blocking Peptide 
respectively at 4°C overnight. The membranes were washed with PBST for 15 minutes at 
room temperature for 3 times. The membranes were incubated in PBST containing anti-
rabbit HRP secondary antibody (1:1000) at 4°C for one hour. The membranes were 
subsequently washed with PBST 15 minutes at room temperature for 3 times. After 
washing, the membranes were visualized with chemiluminescence (Amersham 
Pharmacia Biotech, Little Chalfont, UK). 
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2.6 Measurement of protein kinase A activity 
The cells were seeded on the 6-well plate with seeding density of 3 X 10^ cells 
/ml. The confluent 16HBE14o- cells were harvested on day 9 or 10. The cells were 
incubated in serum-free medium one day before experiment and changed to normal KH 
solution one hour before the experiment. The 16HBE14o- cells were incubated with 
drugs in normal KH solution. After incubation, cells were washed with ice-cold PBS and 
then lysed with 120 |xM lysis buffer in each well. 
The PKA contents of the cell samples were assayed with the PepTag® non-
radioactive cAMP-dependent protein kinase assay system (Promega). PKA activity was 
measured by the quantity of phosphorylated Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly), 
a synthetic substrate specific for PKA. The phosphorylated and non-phosphorylated 
samples were separated on a 0.8 % agarose gel at 100 V for 22 minutes. The gel was 
photographed and the fluorescence intensity was quantified by the SynGene (Version 4.0， 
Cambridge, UK). 
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2.7 Data analysis 
The change of was quantified by the change of Fura-2 fluorescence ratio in 
responses to agonists/drugs. The change of fluorescence ratio was calculated by 
subtracting the fluorescence ratio before stimulation from the peak fluorescence ratio 
stimulated by agonists/drugs. 
For Isc response, since the responses of Isc appear in a biphasic form, i.e. a 
transient first peak and subsequently a second peak, the measurement of Isc responses is 
divided into two parts. For both measurements, change of Isc was calculated by the 
subtraction of Isc measured before stimulation from the peak Isc stimulated with 
agonists/drugs. 
Values are given as mean 土 S.E. (i.e. standard error of the mean) of n 
experiments. The values are also presented in percentage, with control experiment taken 
as 100%. Statistical comparisons were performed by Student's /-test between original 
values prior to normalization, with P < 0.05 considered significant. Curve fitting was 




3.1 Expressions of CysLTi and P2Y6 receptors in 16HBE14o- cell monolayers 
In order to examine the presence of CysLTi and P2Y6 receptors in 16HBE14o-
cells, Western blot analysis was conducted. CysLTi and P2Y6 receptors expression in 
16HBE14o- cells were detected as shown in Fig. 3.1.1 and 3.1.2. The CysLTi 
receptor polyclonal antibody identified an intensive band of 44 kDa in whole cell 
lysates of 16HBE14o- cell monolayers (Fig. 3.1.1, left lane). The specificity of the 
bands was confirmed by the complete abolishment of the immunoreactive signal in 
16HBE40- cells by the CysLTi receptor polyclonal antibody that had been pre-
adsorbed with specific blocking peptides. The blocking peptides correspond to the 
amino acid residues 318-337 from human CysLTi receptor (Fig 3.1.1，right lane). On 
the other hand, P2Y6 receptor was identified an intensive band of 41 kDa (Fig 3.1.2， 
left lane). The specificity of the bands was confirmed by the complete abolishment of 
the immunoreactive signal by the P2Y6 receptor antibody pre-adsorbed with specific 
blocking peptides. The blocking peptides correspond to the amino acid residues 322-
343 from human P2Y6 receptor (Fig 3.1.2, right lane). The Western blot analysis 
demonstrated 16HBE14o- cells expressed both CysLTi receptor and P2Y6 receptor. 
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CysLTi CysLTi antibody + 
antibody blocking peptide 
CysLTi ^ I M P 
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— 3 7 K 
Figure 3.1.1 Western blot analysis of CysLTi receptor in whole cell lysates prepared 
from 16HBE140- cell monolayers. The proteins (50 |xg/lane) were separated by 
12.5% aery lam ide gel. The presence of CysLTi receptor was detected by CysLT] 
receptor polyclonal antibody (1:300; left lane). The Western blot of CysLTi receptor 
was completely abolished by CysLTi receptor blocking peptide (right lane). 
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Figure 3.1.2 Western blot analysis of P2Y6 receptor in whole cell lysates prepared 
from 16HBE140- cell monolayers. The proteins (50 |xg/lane) were separated by 
12.5% acrylamide gel. The presence of P2Y6 receptor was detected by P2Y6 antibody 
(1:250; left lane). The Western blot of P2Y6 receptor was completely abolished by 
P2Y6 receptor blocking peptide (right lane). 
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3.2 Differential inhibitory effects of montelukast, pranlukast and zafirlukast to 
UDP on Isc and [Ca2+�i in 16HBE14o- cells 
3.2.1 Effect of apical or basolateral application of UDP on Isc and 
UDP is the specific agonist of P2Y6 receptor, which has been shown to 
regulate ion transport processes in epithelial cells (Ralevic & Burnstock, 1998). First, 
the effect of apical or basolateral application of UDP in Isc was investigated using 
conventional Ussing chamber study. Fig. 3.2.1.1 shows the representative recordings 
of Isc in response to the apical application of 30 — 300 i^M UDP and the basolateral 
application of 300 |LIM UDP. Addition of UDP to the apical side rapidly increased Isc. 
The Isc change consisted of biphasic responses, namely an initial transient peak (first 
peak) and a second rise peaked within 2 minutes (seond peak). The increase in Isc 
from baseline to the first and second peak values would then be normalized by the 
unit area of the permeable support. Fig. 3.2.1.2 summarizes the change of Isc (AIsc) in 
the first peak induced by UDP application (30 |iM (ap): 4.58 土 1.87 |iA/cm^; 70 joM 
(ap): 15.12 士 3.1 \xA/cm^; 100 [iM (ap): 29.1 士 1.95 |iA/cm^ 300 i^M (ap): 27.85 士 
6.5 ^lA/cm^ 300 i^M (bl): 0.85 士 0.02 |iA/cm^，n = 4-5) ； and Fig. 3.2.1.3 summarizes 
the change of Isc (AIsc) in the second peak upon stimulation in the same set of 
experiments (30 \ M (ap): 4.22 土 1.5 }xA/cm^ 70 |xM (ap): 14.12 士 2.98 |iA/cm^ 100 
^M (ap): 23.42 士 3.02 ^lA/cm^; 300 [lU (ap): 22.1 士 2.6 |iA/cm^ 300 ^M (bl): 0.5 士 
0.01 ^A/cm^ n = 4-5). 
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In another series of experiments, intracellular calcium concentration was 
measured in 16HBE14o- cells grown on glass coverslips using fluorescent technique. 
Fig. 3.2.1.4 showed the representative recordings of [Ca"^]i in response to 30 - 300 
|xM UDP application, respectively. The changes in are obtained by measuring 
the maximal rise of the 340/380 nm fluorescence ratio upon stimulation. Summarized 
data is shown in Fig. 3.2.1.5 (30 |iM: 0.001 士 0.0020 units; 70 |xM: 0.0102 士 0.0004 
units; 100 |xM: 0.0275 士 0.0005 units; 300 0.0248 士 0.0026 units, n = 5-6). 
Apical application of UDP elicited a concentration-dependent increase in the 
first peak of Isc, with UDP concentration of 100 |iM eliciting the maximum increase in 
Isc. The increase in second peak of Isc also exhibited a concentration-dependent 
relationship with the apical application of UDP, again with 100 |LIM UDP eliciting the 
maximum increase in Isc. The addition of basolateral UDP evoked only a small and 
variable increase in Isc in both phases. Due to the small response of basolateral UDP-
induced Isc, only Uc induced by apical addition of UDP would be investigated in the 
following sessions. The increase in upon addition of UDP also showed 
concentration dependency, again with 100 joM UDP inducing the largest increase in 
[Ca2+]i. In short, apical UDP application stimulated an increase in Isc and and 
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Figure 3.2.1.1 Representative recordings of Isc in response to the apical and 
basolateral application of UDP. 16HBE14o- cells were initially bathed with normal 
Krebs-Henseleit (KH) solution. The apical KH solution was then changed to a KH 
solution with reduced CI" concentration. The addition of different concentration of 
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Figure 3.2.1.2 Concentration-dependent effect of apical or basolateral UDP on 
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Figure 3.2.1.3 Concentration-dependent effect of apical or basolateral UDP on 
changes of second Isc peak. Each column represents the mean 士 S.E. (n = 4-5). 
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Figure 3.2.1.4 Representative recordings of [Ca""^ ]i in response to the application of 
UDP. 16HBE140- cells were initially perfused with normal Krebs-Henseleit (KH) 
solution. The KH solution was then changed to a Ca^^ free KH solution. The addition 
of different concentrations of UDP is shown by the arrows. Data presented are 
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Figure 3.2.1.5 Concentration-dependent effect of UDP on changes in (AFura-
2 ratio) in response to UDP application (30 - 300 |xM). Each column represents the 
mean 士 S.E. (n = 4-5). 
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3.2.2 Effect of montelukast to the application ofUDP on Isc and [Ca^ J^i 
It has been shown that there is a crosstalk between CysLTi receptor and P2Y6 
receptors in epithelial cells (Mellor et al, 2001; Capra et al, 2005). In the present 
study, the effect of three commonly used CysLTi antagonists (montelukast, pranlukast 
and zafirlukast) to UDP, a P2Y6 agonist, on Isc and were measured in 
16HBE140- cells. The specificity of these three CysLTi antagonists to CysLTi 
receptor is: montelukast > pranlukast > zafirlukast (Ravasi et al” 2002). We first 
investigated the effect of montelukast to the UDP-induced Isc and 
For the Isc, the epithelia was pretreated with various concentrations (0.3 - 3 
|iM) of montelukast at either apical or basolateral side, followed by apical addition of 
100 \iM UDP. Fig. 3.2.2.1 shows the representative recordings of Isc in response to the 
application of 100 |xM UDP in the presence of montelukast (0.3 - 3 |iM) at either 
apical or basolateral side. Fig. 3.2.2.2 summarizes the changes of first peak of Isc in 
response to the application of 100 |iM UDP with the apical or basolateral pre-
treatment of montelukast. Fig. 3.2.2.3 summarizes the change of second peak of Isc in 
the same set of experiments. Fig. 3.2.2.4 shows the representative recordings of 
[Ca"^]i in response to the application of 100 |jM UDP in the presence of montelukast 
(0.3 - 3 |j.M) and Fig. 3.3.2.5 shows the summarized data. 
As mentioned in Section 3.2.1, the UDP-induced Isc responses could be 
divided into two components reflecting first and second peaks. Thus, the 
measurement of Isc responses consists of two parts. The values would then be 
normalized to the growth area of the permeable support. To facilitate comparison, the 
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percentage of inhibition would also be calculated. Based on the Isc responses 
measured by the method above, the percentage of inhibition was obtained by [(/ cysui 
antagonist _ / control)/ I control] X 100%, whcrC I CysLTl antagonist WaS the peak magnitude of 
the UDP-induced Isc response under the pre-treatment of montelukast. I control was the 
peak magnitude of the UDP-induced Isc without any pre-treatment. The percentage of 
inhibition of montelukast on UDP-induced was also obtained by the same 
formula as above, where I cysm antagonist was the peak magnitude of the UDP-induced 
[Ca~^]i response under the pre-treatment of CysLTi antagonists. I control was the peak 
magnitude of the UDP-induced without any pre-treatment. 
Both the first and second peaks of Isc were analyzed. In the presence of apical 
montelukast, UDP-induced first peak was reduced in a concentration-dependent 
manner (control: 29.1 士 1.95 |iA/cm^ n = 4; 0.3 i^M (ap): 29.75 士 2.0 |iA/cm^, n = 4; 
0.7 \M (ap): 20.63 士 1.8 ^lA/cm^p < 0.05, n = 4; 1 |iM (ap): 12.35 士 1.4 )iA/cm^p < 
0.01’ n = 5; 3 i^M (ap): 13.96 士 1.8 {jA/cm�，p < 0.01, n = 5, Fig. 3.2.2.2). However, 
basolateral pre-treatment of the epithelia with montelukast could not inhibit UDP-
induced first peak (Fig. 3.2.2.2). Similarly, both apical and basolateral application of 
montelukast had no significant effect on the second peak (Fig. 3.2.2.3). The UDP-
induced [Ca-^i was also reduced by 17.54 土 221 %, 50.88 士 2.88 % and 56.14 士 3.4 
% in the presence of 0.7, 1 or 3 |iM of montelukast, respectively (control: 0.0275 士 
0.0005 units, n = 5; 0.7 ^iM: 0.0227 土 0.0004 units, p < 0.05, n = 4; 1 \M: 0.0135 士 
0.0040 units, p < 0.01, n = 5; 3 0.0121 士 0.0005 units, p < 0.01, n = 5, Fig. 
3.2.2.5). The half maximal inhibitory concentration (IC50) of montelukast to the UDP-
induced Isc and [Ca2+]i is 0.81 and 1.04 |jM，respectively. Fig. 3.3.2.6 shows the 
concentration response curve of UDP-induced [Ca~^]i induced by various 
Results 1 ] 2 
concentrations of UDP (10 - 300 jiM) in the presence of 1 |j.M montelukast. The data 
shows thatl )iM montelukast significantly inhibited the [Ca"^]i responses induced by 
100 i^ M UDP (without montelukast: 1.0 士 0.042; with montelukast: 0.72 士 0.049，/? < 
0.05, n = 6-7，Fig. 3.2.2,6). Taken together, the data demonstrated that montelukast 
inhibited UDP-induced (first peak only) and [Ca'"^]i increases, respectively. 
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Figure 3.2.2.1 Representative recordings of Isc in response to the apical (ap) 
application of 100 \iM UDP in the presence of montelukast. 16HBE14o- cells were 
initially bathed with normal Krebs-Henseleit (KH) solution. The apical KH solution 
was then changed to a KH solution with reduced CI" concentration. Apical (A) or 
basolateral (B) montelukast was applied 10 minutes before the application of UDP. 
The additions of UDP and montelukast are shown by the arrows. Figures are 
representatives of at least four independent experiments. 
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Figure 3.2.2.2 Effect of montelukast on first peak of Isc in response to the apical 
application of 100 |iM UDP. Control was the apical application of 100 \iM UDP in 
the absence of montelukast (n = 4). The apical (ap) (n = 4-5) or basolateral (bl) (n = 6) 
addition of montelukast (0.3 - 3 |iM) was applied 10 minutes prior to the addition of 
UDP to the 16HBE140- cells. Each column represents the mean ± S.E. Statistical 
differences between the pretreated groups and control are indicated by *P < 0.05 and 
< O.OJ (Student Mest). 
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Figure 3.2.2.3 Effect of montelukast on second peak of Isc in response to the apical 
application of 100 i^M UDP. Control was the apical application of 100 |xM UDP in 
the absence of montelukast (n = 4). The apical (ap) (n = 4-5) or basolateral (bl) (n = 6) 
addition of montelukast (0.3 - 3 \M) was applied 10 minutes prior to the addition of 
UDP to the 16HBE140- cells. Each column represents the mean 士 S.E. No statistical 
difference between the pretreated groups and the control groups are observed (Student 
/-test). 
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Figure 3.2.2.4 Representative recordings of [Ca"^]i in response to the application of 
UDP in the presence of montelukast. 16HBE14o- cells were initially perfused with 
normal Krebs-Henseleit (KH) solution. The KH solution was then changed to Ca^^ 
free KH solution. Montelukast was applied 10 minutes before the application of UDP. 
The additions of UDP and montelukast are shown by the arrows. Figures are 
representatives of at least four independent experiments. 
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Figure 3.2.2.5 Effect of montelukast to [Ca"^]i (AFura-2 Ratio) in response to the 
application of 100 UDP in a Ca^^ free KH solution. Control was the application of 
100 i^M UDP in the absence of montelukast (n 二 5). Variuos concentrations of 
montelukast (0.3 - 3 |xM; n = 4-5) was applied 10 minutes prior to the addition of 100 
laM UDP. Each column represents the mean 士 S.E. Statistical differences between the 
pretreated groups and control are indicated by *P < 0.05 and **P < 0.01 (Student /-
test). 
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Figure 3.2.2.6 Effect of montelukast to (AFura-2 Ratio) in response to the 
application of UDP in a free KH solution. Cells were stimulated with various 
concentrations of UDP with (Red circle) or without (White circle) 1 |LIM of 
montelukast (n = 6). Each data point represents the mean 土 S.E. Statistical differences 
between the pretreated groups and control are indicated by *P < 0.05 (Student /-test). 
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3.2.3 Effect of pranlukast to the application of UDP on Isc and 
Fig. 3.2.3.1 shows the representative recordings of Isc in response to the 
application of 100 jxM UDP in the presence of pranlukast (0.3 - 3 |iM) at either apical 
or basolateral side. Fig. 3.2.3.2 summarizes the changes of first Isc peak in response to 
the application of 100 )LIM UDP with the apical and basolateral pre-treatment of the 
epithelia with pranlukast. Fig. 3.2.3.3 summarizes the change of second Isc peak in the 
same set of experiments. Fig. 3.2.3.4 shows the representative recordings of [Ca~^]i in 
response to the application of 100 |LIM UDP in the presence of pranlukast (0.3 - 3 
|LIM). Fig. 3.2.3.5 shows the summarized data. 
The data shows that, similar to montelukast, the UDP-induced first Isc peak 
was inhibited in a concentration-dependent manner by apical but not basolateral pre-
treatment of the epithelia with pranlukast (control: 29.1 士 1.95 |iA/cm^, n = 4; 0.3 |iM 
(ap): 27.42 土 1.31 ^lA/cm^ n = 5; 0.7 i^M (ap): 20.56 士 3.68 |iA/cm^ n = 5; 1 ^M 
(ap): 13.18 土 0.61 )iA/cm^ p < 0.01, n = 5; 3 i^M (ap): 14.00 士 2.90 |iA/cm^ p < 
0.01, n = 6; 0.3 i^M (bl): 22.98 士 4.33 |iA/cm^ n = 6; 0.7 |iM (bl): 28.48 士 2.55 
^lA/cm�，n = 5; 1 i^M (bl): 25.93 士 2.04 |iA/cm^ n = 4; 3 |LIM (bl): 28.17 士 2.97 
)iA/cm^, n = 4, Fig. 3.2.3.2). Again, the UDP-induced second Isc peak was not 
inhibited by either apical or basolateral application of pranlukast (Fig. 3.2.3.3). In 
contrast to the data of montelukast, UDP-induced [Ca^^Ji was not significantly 
reduced by pranlukast (Fig. 3.2.3.4 - 3.2.3.5). The data demonstrates that pranlukast 
inhibited UDP-induced Isc change (first peak only) but failed to cause any inhibitory 
effect on UDP-induced increase. 
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Figure 3.2.3.1 Representative recordings of Isc in response to the apical (ap) and 
basolateral (bl) application of 100 fxM UDP in the presence of pranlukast. 16HBE14o-
cells were initially bathed with normal Krebs-Henseleit (KH) solution. The apical KH 
solution was then changed to a KH solution with reduced CI" concentration. Apical (A) 
or basolateral (B) pranlukast was applied 10 minutes before the application of UDP. 
The additions of UDP and pranlukast are shown by the arrows. Figures are 
representatives of at least four independent experiments. 
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Figure 3.2.3.2 Effects of pranlukast on first peak of Isc in response to the apical 
application of 100 |liM UDP. Control was the apical application of 100 |liM UDP in 
the absence of pranlukast (n = 4). The apical (ap) (n = 4-5) or basolateral (bl) (n = 4-
5) pranlukast was applied 10 minutes prior to the addition of UDP to the 16HBE14o-
cells. Each column represents the mean 士 S.E. Statistical differences between the 
pretreated groups and control are indicated by **P < 0.01 (Student /-test). 
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Figure 3.2.3.3 Effects of pranlukast on second peak of Isc in response to the apical 
application of 100 )iM UDP. Control was the apical application of 100 |j.M UDP in 
the absence of pranlukast (n = 4). The apical (ap) (n = 4-5) or basolateral (bl) (n = 4-
5) pranlukast (0.3 - 3 |iM) was applied 10 minutes prior to the addition of UDP to the 
16HBE140- cells. Each column represents the mean 士 S.E. No statistical difference 
between the pretreated groups and the control groups are observed (Student /-test). 
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Figure 3.2.3.4 Representative recordings of [Ca~ ]^i in response to the application of 
UDP in the presence of pranlukast. 16HBE14o- cells were initially perfused with 
normal KH solution. The KH solution was then changed to Ca^ "^  free KH solution. 
Various concentrations of pranlukast were applied 10 minutes prior to the addition of 
UDP to the 16HBE140- cells. The additions of UDP and pranlukast are shown by the 
arrows. Figures are representatives of at least four independent experiments. 
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Figure 3.2.3.5 Effect of pranlukast to (AFura-2 Ratio) in response to the 
application of 100 |iM UDP in a Ca2+ free KH solution. Control was the application of 
100 |iM UDP in the absence of pranlukast (n = 5). Various concentrations of 
pranlukast (0.3 - 3 |iM; n = 4-5) was applied 10 minutes prior to the addition of 100 
|iM UDP. Each column represents the mean 士 S.E. No statistical difference between 
the pretreated groups and the control groups are observed (Student /-test). 
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3.2.4 Effect of zafirlukast to the application of UDP on Isc and [Ca^+h 
Fig. 3.2.4.1 shows the representative recordings of Isc in response to the 
application of 100 |liM UDP in the presence of zafirlukast (0.3 - 3 |IM) at apical or 
basolateral side. Fig. 3.2.4.2 summarizes the change of first Isc peak in response to the 
application of 100 \iM UDP with the apical or basolateral addition of zafirlukast. Fig. 
3.2.4.3 summarizes the change of second Isc peak in the same set of experiments. Fig. 
3.2.4.4 shows the representative recordings of in response to the application of 
100 fxM UDP in the presence of zafirlukast (0.3 - 3 |xM) and Fig. 3.2.4.5 shows the 
summarized data. 
Similar to pranlukast, apical application of zafirlukast effectively inhibited 
UDP-induced first Isc peak and the inhibition was less prominent in low concentration 
of zafirlukast. In the presence of 0.7, 1 or 3 )iM of apical zafirlukast, UDP-induced 
first Isc peak were reduced by 11.75 士 3.65 %，49.06 士 1.40 % and 50.03 士 5.12 % 
(control: 29.1 士 1.95 |iA/cm^ n = 4; 0.7 \iU (ap): 25.68 土 1.06 |iA/cm^ n = 6; 1 iiM 
(ap): 14.82 士 0.41 |iA/cm^ p < 0.01, n = 5; 3 [M (ap): 14.54 士 1.49 \iAJcm^, p < 
0.01, n = 5, Fig. 3.2.4.2); whilst basolateral application of zafirlukast could not inhibit 
the UDP-induced first Isc peak (Fig. 3.2.4.2). Again, neither apical nor basolateral 
application of zafirlukast inhibited the UDP-induced second Isc peak significantly 
(Fig. 3.2.4.3). Similar to pranlukast, UDP-induced was not significantly 
reduced by zafirlukast (Fig. 3.2.4.4). The data demonstrated that zafirlukast inhibited 
UDP-induced Isc change (first peak only) but failed to cause any inhibitory effect on 
UDP-induced increase. 
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Figure 3.2.4.1 Representative recordings of Isc in response to the apical (ap) and 
basolateral (bl) application of 100 |j,M UDP in the presence of zafirlukast. 
16HBE140- cells were initially bathed with normal Krebs-Henseleit (KH) solution. 
The apical KH solution was then changed to a KH solution with reduced CI" 
concentration. Apical (A) or basolateral (B) zafirlukast was applied 10 minutes before 
the application of UDP. The additions of UDP and zafirlukast are shown by the 
arrows. Figures are representatives of at least four independent experiments. 
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Figure 3.2.4.2 Effect of zafirlukast on first Isc peak in response to the apical 
application of 100 |xM UDP in a KH solution with reduced CI" concentration. Control 
was the apical application of 100 |j.M UDP without pre-treatment of the epithelia with 
zafirlukast (n = 4). The apical (ap) (n = 4) or basolateral (bl) (n = 4-5) addition of 
zafirlukast (0.3 - 3 |iM) was applied 10 minutes prior to the addition of UDP to the 
16HBE140- cells. Each column represents the mean 士 S.E. Statistical differences 
between the pretreated groups and control are indicated by **P < 0.01 (Student t-
test). 
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Figure 3.2.4.3 Effect of zafirlukast on second Isc peak in response to the apical 
application of 100 )iM UDP in a KH solution with reduced CI" concentration. Control 
was the apical application of 100 |xM UDP in the absence of zafirlukast (n = 4). The 
apical (ap) (n = 4) or basolateral (bl) (n = 4-5) addition of zafirlukast (0.3 - 3 \iM) 
was applied 10 minutes prior to the addition of UDP to the 16HBE14o- cells. Each 
column represents the mean 士 S.E. No statistical difference between the pretreated 
groups and the control groups are observed (Student /-test). 
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Figure 3.2.4.4 Representative recordings of [Ca"^]i in response to the application of 
UDP in the presence of zafirlukast. 16HBE14o- cells were initially perfused with 
normal KH solution. The KH solution was then changed to Ca"^ free KH solution. 
Various concentrations of zafirlukast (0.3 - 3 fiM; n = 5-6) were applied 10 minutes 
prior to the addition of UDP to the 16HBE14o- cells. The additions of UDP and 
zafirlukast are shown by the arrows. 
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Figure 3.2.4.5 Effect of zafirlukast to [Ca~^]i (AFura-2 Ratio) in response to the 
application of 100 |xM UDP in a Ca^^ free KH solution. Control was the application of 
100 )LIM UDP without zafirlukast (n = 5). Various concentrations of pranlukast (0.3 -
3 |xM; n = 5-6) was applied 10 minutes prior to the addition of 100 \iM UDP. Each 
column represents the mean 士 S.E. No statistical difference between the pretreated 
groups and the control groups are observed (Student /-test). 
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3.2.5 Summary of the effects of montelukast, pranlukast and zafirlukast to UDP 
application on Isc and 
The effects of montelukast, pranlukast and zafirlukast to UDP application on 
Isc and [Ca2+]i were compared. In general, all three CysLTi antagonists inhibited 
UDP-induced first Isc peak, with montelukast causing the largest inhibition. However, 
second Isc peak was not be influenced by these antagonists. Data also showed that of 
the three CysLTi antagonists, only montelukast inhibited the UDP-induced [Ca^^Ji 
increase in a concentration dependent manner. Concentration of 1 |xM of the three 
CysLTi antagonists was used to perform further investigations in the following 
sessions because 1 fxM of CysLTi antagonists caused maximal or nearly maximal 
inhibition on the UDP-induced Isc and P2Y6 receptors have been shown to 
couple to two independent signalling pathways, causing an increase in intracellular 
calcium (Kottgen et al.’ 2003). Recently, we have also demonstrated that P2Y6 
receptors couple to both Ca^^ and cAMP pathways in 16HBE14o- cells (Wong et al” 
2009). Thus, these two Ca^^- and cAMP-dependent pathways would be investigated 
in the following sessions. 
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3.3 Cellular mechanism(s) underlying the effect of montelukast to apical UDP 
application on 16HBE14o- cells 
In the present study, the underlying mechanism(s) of montelukast in the 
inhibition of UDP-induced and Isc was further investigated. The elevation of 
[Ca"^]i is caused by an increased production of inositol trisphosphate (IP3)，which is 
triggered by the coupling of P2Y6 receptors with phospholipase C (PLC) upon 
addition of UDP (Brunschweiger & Mueller et al., 2006). Besides an increase in 
[Ca2+]i，UDP also causes cAMP production, which in turn could activate protein 
kinase A (PKA) and an Exchange protein directly activated by cAMP (Epac) (De 
Rooij et al.’ 1998; Ster et al., 2007; Cheng et al., 2008). Thus, various drugs involving 
in the Ca^^- and cAMP-dependent pathway were used to uncover the cellular 
mechanism(s) induced by UDP that these three CysLTi antagonists may interfere. 
3.3.1 Effect of various blockers inhibiting Ca^^-dependent pathway on UDP-
induced [Ca2+]i in the presence or absence of montelukast 
As mentioned above, the increase in [Ca"^]i is caused by the coupling of P2Y6 
receptors with phospholipase C (PLC) and hence the production of the IP3 
(Brunschweiger & Mueller et al” 2006). Two pharmacological agents, namely, 
U73122 and xestospongin C (XeC), were used. U73122 is a specific inhibitor of PLC 
(Smith et al, 1990; Bleasdale et al.’ 1990); whereas XeC is a novel blocker of IP3 
receptor (Gafini et al.’ 1997; Hu et al., 1999). 
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In the experiment, the cells were perfused with normal KH solution containing 
2.5 rtiM Ca2+，which was then changed to a Ca^ "^  free KH solution. XeC in various 
concentrations were added 10 minutes before the application of 100 |LIM UDP. Under 
the pre-treatment of the epithelia with 0.1, 1 or 3 |iM XeC, the UDP-induced 
response reduced to 73.68 士 1.65，50.55 士 3.5 and 1.10 士 1.0 % of the control 
response (control: 0.0275 士 0.0005 units, n = 6; 0.1 |iM XeC: 0.0203 士 0.005 units, n 
=6，p<0.05\ 1 i^M XeC: 0.0139 士 0.009 units, n = 5, p<0.05; 3 |iM XeC: 0.0003 士 
0.0002 units, n = 5, p<0.005, Fig. 3.3.1.1 - 3.3.1.2). The experiments were performed 
by co-incubation of 1 |xM montelukast and 0.1 |xM XeC. 0.1 jxM XeC was selected to 
facilitate the comparison of inhibition of the [Ca"^]i response by montelukast and co-
incubation of montelukast and XeC. The UDP-induced response reduced to 
71.86 士 3.24 % of control response (A reduced from 0.0275 士 0.0005 units to 
0.0197 土 0.0009 units, two-way ANOVA, p<0.01, n = 6，Fig. 3.3.1.3 - 3.3.1.4). As 
shown in Fig. 3.2.2.4, 1 |4.M montelukast reduced UDP-induced response to 
49.12 ± 2.88 % of control response (A reduced from 0.0275 士 0.00052 units to 
0.0135 士 0.004 units,p < 0.01, n = 5). By comparing the inhibition induced by the co-
incubation of montelukast and XeC and the inhibition induced by montelukast alone, 
co-incubation of XeC and montelukast failed to cause additional inhibition to the 
UDP-induced increase. Notably, the co-incubation treatment reduces the 
inhibitory effect of montelukast by 22.74%. The summarized data is shown in Fig. 
3.3.1.5. The data shows that montelukast may interfere with the signalling pathway at 
a level upstream to IPs-induced Ca"^ release. 
To investigate whether montelukast may act upstream of IPs-induced Ca'"^ 
release, U73122 was used to inhibit the PLC activity. Similar to XeC, 0.1, 1 and 3 i^M 
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U73122 reduced the UDP-induced [Ca '^^ Ji response to 64.40 士 3.45, 40.66 士 5.60 and 
5.2 士 2.1 % of control response (control: 0.0275 士 0.0005 units, n = 6; 0.1 |iM 
U73122: 0.0177 士 0.005 units, n = 6, p<0.05\ 1 i^M U73122: 0.0112 士 0.010 units, n 
=5，p<0.05\ 3 |xM XeC: 0.0014 士 0.0007 units, n = 6，p<0.005, Fig. 3.3.1.6 -
3.3.1.7). Again, the data demonstrates that co-incubation of 0.1 |a,M U73122 and 1 [iM 
montelukast reduced UDP-induced response to 63.16 士 2.55 % of the control 
response (A reduced from 0.0275 土 0.0005 units to 0.0173 土 0.0007 units, 
two-way ANOVA, p < 0.05, n = 5 units, Fig. 3.3.1.8 - 3.3.1.9) and failed to cause 
additional inhibition to the UDP-induced [Ca^^Ji increase. Similar to XeC, the co-
incubation reduces montelukast's inhibitory effect on UDP-induced [Ca^^Jj increase 
by 14.04 %. The summarized data is shown in Fig. 3.3.1.10. The data suggest that 
montelukast may interfere the pathway at a level upstream to the PLC activity and the 
production of IP3. 
In the next series of experiments, the effect of montelukast on Ca"^ influx was 
investigated. As mentioned above, the cells were perfused with Ca^ "^  free KH solution. 
To investigate the Ca^ "^  influx, free KH solution was changed to normal KH 
solution after the application of 100 |j.M UDP. An influx of Ca'^ was induced and 
resulted to a [Ca2+]i response of 0.0205 士 0.0008 unit. In the presence of montelukast, 
the [Ca"^]i response induced by changing the Ca""^  free KH solution to normal KH 
solution did not alter significantly (0.0209 士 0.0009 unit, n = 5). The data suggests 
that montelukast has no effect on the Ca""^  influx from external environment. Data is 
shown in Fig. 3.3.1.11 -3.3.1.12. 
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Taken together, it is likely that montelukast interferes with the Ca^'^-dependent 
pathway at a level above IP3 production and PLC activity, probably at the P2Y6 
receptor level. By blocking the receptor, montelukast hence blocks the activation of 
PLC and the production of IP3. 
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Figure 3.3.1.1 Representative recordings of in response to the application of 
100 |LIM UDP, with or without xestospongin C (XeC). 16HBE14o- cells were initially 
perfused with normal KH solution. The KH solution was then changed to Ca^ "^  free 
KH solution. Control cells were stimulated with the application of 100 |iM UDP alone 
(n = 4). Treated cells were pre-treated with XeC of various concentrations 10 minutes 
prior to the application of 100 i^M UDP (n = 5-6). The additions of UDP and XeC are 
shown by the arrows. 
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Figure 3.3.1.2 Effect of xestospongin C (XeC) on in response to the 
application of 100 |iM UDP in a Ca^ "" free KH solution. 16HBE14o- cells were pre-
treated with 0.1 \ M XeC prior to the application of 100 \M UDP (n = 5). Control was 
the application of 100 |LIM UDP alone (n = 4). Each column represents the mean ± 
S.E. Statistical difference between the XeC-pretreated groups and control is indicated 
by **P< 0.01, ***<P<0.005 (Student/-test). 
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Figure 3.3.1.3 Representative recordings of [Ca'^Ji in response to the application of 
100 |xM UDP, with or without co-incubation of montelukast and xestospongin C 
(XeC). 16HBE140- cells were initially perfused with normal KH solution. The KH 
solution was then changed to free KH solution. Control cells were stimulated 
with the application of 100 )xM UDP only (n = 4). Treated cells were co-incubated 
with 1 i^ M XeC andl jiM montelukast 10 minutes prior to the application of 100 |iM 
UDP (n = 5-6). The additions of UDP, montelukast and XeC are shown by the arrows. 
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Figure 3.3.1.4 Effect of co-incubation of xestospongin C (XeC) and montelukast on 
[Ca2+]i in response to the application of 100 )iM UDP in a Ca""^  free KH solution. 
1 6 H B E 1 4 0 - cells were co-incubated with 0.1 \M XeC and 1 |LIM montelukast prior to 
the application of 100 |LIM UDP (n = 6). Control was the application of 100 |xM UDP 
alone (n = 5). Each column represents the mean 士 S.E. Statistical difference is 
indicated by < 0.01 (Student Mest). 
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Figure 3.3.1.5 Summary of the effects of xestospongin C (XeC) and montelukast pre-
treatment on [Ca~^]i (AFura-2 ratio) in response to the application of 100 |xM UDP in 
a Ca2+ free KH solution. 16HBE14o- cells were pre-treated with 1 |iM montelukast (n 
=4-6)，0.1 |4.M XeC (n = 5)，or co-incubation with 1 |xM montelukast and 0.1 \iM 
U73122 prior to the application of 100 |xM UDP (n = 6). Control was the application 
of 100 |iM UDP alone (n = 4). Each column represents the mean 士 S.E. Statistical 
difference between the treated groups and control is indicated by **P < 0.01 and NS: 
not significant (Two-way ANOVA). 
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Figure 3.3.1.6 Representative recordings of [Ca"^]i in response to the application of 
100 ^M UDP, with or without U73122. 16HBE14o- cells were initially perfused with 
normal KH solution. The KH solution was then changed to Ca^^ free KH solution. 
Control cells were stimulated with the application of 100 |iM UDP alone (n = 4). 
Treated cells were pre-treated with U73122 of various concentration 10 minutes prior 
to the application of 100 |iM UDP (n = 5-6). The additions of UDP and U73122 are 
shown by the arrows. 
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Figure 3.3.1.7 Effect of U73122 on in response to the application of 100 jiM 
UDP in a Ca2+ free KH solution. 16HBE14o- cells were pre-treated with 0.1 \iM 
U73122 prior to the application of 100 |iM UDP (n = 6). Control was the application 
of 100 |j.M UDP alone (n = 4). Each column represents the mean 土 S.E. Statistical 
difference between the U73122-pretreated groups and control is indicated by **P < 
0.01’ ***P<0.005 (Student Mest). 
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Figure 3.3.1.8 Representative recordings of in response to the application of 
100 i^ M UDP, with or without co-incubation of montelukast and U73122. 16HBE Mo-
cells were initially perfused with normal KH solution. The KH solution was then 
changed to Ca^^ free KH solution. Control cells were stimulated with the application 
of 100 ^M UDP alone (n = 4). Treated cells were pre-treated with 0.1 |iM U73122 
and 1 |xM montelukast 10 minutes prior to the application of 100 \iM UDP (n = 5-6). 
The additions of UDP, montelukast and U73122 are shown by the arrows. 
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Figure 3.3.1.9 Effect of co-incubation of U73122 and montelukast on in 
response to the application of 100 |iM UDP in a Ca"^ free KH solution. 16HBE Mo-
cells were co-incubated with 0.1 jiM U73122 and 1 |iM montelukast prior to the 
application of 100 ^M UDP (n = 6). Control was the application of 100 jiM UDP 
alone (n = 5-6). Each column represents the mean 士 S.E. Statistical difference is 
indicated by *P < 0.05 (Student Mest). 
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Figure 3.3.1.10 Summary of the effects of U73122 and montelukast on 
(AFura-2 ratio) in response to the application of 100 |iM UDP in a Ca"^ free KH 
solution, 16HBE140- cells were pre-treated with 1 |iM montelukast (n = 4-6), 1 i^ iM 
U73122 (n = 5), or co-incubation with 1 [M montelukast and 0.1 \lM U73122 prior to 
the application of 100 i^M UDP (n = 6). Control was the application of 100 i^M UDP 
alone (n = 4). Each column represents the mean 士 S.E. Statistical difference between 
the treated groups and control is indicated by < 0.05 and NS: not significant (Two-
way ANOVA). 
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Figure 3.3.1.11 Representative recordings of UDP-induced influx, in the 
absence or presence of montelukast. 16HBE14o- cells were initially perfused with 
Ca^+free KH solution and stimulated with 100 |iM UDP. Subsequent to the response, 
the Ca2+ free KH solution was then changed to normal KH solution containing 2.5 
mM Ca"^. A: Cells were stimulated with the application of 100 \iM UDP alone (n = 
6). B: Cells were pretreated with 1 \iM montelukast 10 minutes prior to the 
application of UDP (n = 5). 
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Figure 3.3.1.12 Effect of montelukast to UDP-induced Ca^^ influx, in response to the 
change from Ca"^ free KH solution to normal KH solution. Control was the 
application of 100 \iM UDP alone (n = 6). Cell were pretreated with 1 )iM 
montelukast before the application of UDP (n = 5). Each column represents the mean 
士 S.E. No statistical difference between the control and pretreated groups was 
observed (Student /-test). 
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3.3.2 Effects of montelukast, pranlukast and zafirlukast to PKA or Epac on Isc 
induced by apical UDP 
As mentioned in section 3.3, besides an increase in UDP also 
evidently stimulates cAMP production (Schreiber et aL, 2005), which in turn could 
activate protein kinase A (PKA) and an exchange protein directly activated by cAMP 
(Epac) (Rooij et al.，1998; Ster et al., 2007; Cheng et aL’ 2008). In the present study, 
forskolin, 8-Br-cAMP, 8-CPT-2'-0-Me-cAMP, Sp-6-Phe-cAMPs and a PKA assay 
were employed to investigate the involvement of a cAMP cascade. Forskolin activates 
adenylate cyclase and thus increases the intracellular level of cAMP (Lortet et al” 
1999; Kopperud et al” 2003). 8-Br-cAMP is a cAMP analogue, which potentiates the 
cAMP-dependent response and could activate both PKA and Epac (Chaudhuri et al.， 
2005; Ster et aL, 2007). 8-CPT-2'-0-Me-cAMP is a specific activator of Epac (Kang 
et al” 2003; Holz et aL, 2008). Sp-6-Phe-cAMPs is also a potent PKA activator. 
However, it does not activate Epac and thus can serve as an Epac-negative control (Li 
et al.’ 2007; Adamson et al” 2008). 
Similar to the previous experiments as described in section 3.3.1, the 
percentage of control was obtained by (/ blocker 丨 / control) X 100%, where I blocker was 
the peak magnitude of the UDP-induced Uc response under the pre-treatment of the 
epithelia with blockers. I control was the peak magnitude of the UDP-induced Isc 
without prior addition of the blockers. On the other hand, the percentage of 
potentiation was obtained by (/ potentiator / 1 control) X 100%, where I potentiator was the 
peak magnitude of the UDP-induced Isc response in the presence of the potentiators. I 
control was the peak magnitude of the UDP-induced Isc without any pre-treatment. 
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The Isc in response to the addition of 100 |iM apical UDP was measured as an 
indicator for the ionic transport resulting from activation of cAMP production, and 
thus the activation of PKA and Epac pathways. The PKA and Epac activators 
mentioned above were added about 10 minutes prior to the application of UDP. As 
shown in Fig. 3.3.2.1 - 3.3.2.3’ forskolin (1 jxM) potentiated both the first and second 
peaks of Isc induced by UDP. The percentage increases of the first and second peaks 
were 198 士 9.22 % (Isc potentiated from 17.50 士 1.95 iiA/cm" to 34.75 士 2.40 ^lA/cm^ 
p<0.01, n = 4-6) and 120 士 13.40 % (Isc potentiated from 21.30 士 3.90 iiA/cm" to 
25.60 士 2.85 |jA/cm^, p<0.05, n = 4-6)，respectively. 1 |iM of montelukast, pranlukast 
or zafirlukast were co-incubated with forskolin to the cells 10 minutes prior to the 
addition of UDP. Both the first and second peaks of Isc were measured and analyzed. 
The UDP-induced first peak was significantly reduced by pranlukast to 43.65 士 5.99 
% (Isc reduced from 34.75 士 2.40 |iA/cm^ to 15.80 士 1.88 ^lA/cm^ p<0.01, n = 4-6). 
Similarly, zafirlukast reduced the UDP-induced first peak to 86.99 士 9.67 % (Isc 
reduced from 34.75 士 2.40 ^A/cm" to 27.53 ± 2.39 [lA/cm^, p<0.05, n = 4-6). 
However, montelukast could not reduce the UDP-induced first Isc peak potentiated by 
forskolin. On the other hand, the second Isc peak potentiated by forskolin was not 
reduced by these three CysLTi antagonists. Summarized data is in Fig. 3.3.2.4 — 
3.3.2.6. The data shows that the forskolin-induced cAMP signalling was affected by 
pranlukast and zafirlukast, but unlikely by montelukast. 
Similarly, 8-Br-cAMP, a cAMP analogue, potentiated the first and second 
peaks of Isc to 165.54 士 13.78 % (Isc potentiated from 17.50 士 1.95 ^lA/cm^ to 28.96 士 
3.80 |iA/cm^p<0.01, n = 4-6) and 180.5 士 28.80 % (Isc potentiated from 21.30 士 3.90 
|iA/cm^ to 38.45 士 6.13 |iA/cm^, p<0.05, n = 4-6)，respectively. Again, experiments 
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were conducted to test whether the UDP-induced Isc potentiated by 8-Br-cAMP could 
be inhibited by CysLTi antagonists. For the first Uc peak, pranlukast and zafirlukast 
reduced the response to 42.12 士 6.11 % (Isc reduced from 28.96 土 3.90 |iA/cm^ to 
12.20 士 1.77 \iA/cm\ p<0.01, n = 4-6) and 62.95 士 5.32 % (Isc reduced from 28.96 士 
3.90 nA/cm- to 18.23 士 1.54 [lA/cm-, p<0.05, n = 4-6), respectively; whilst 
montelukast failed to reduced the initial Isc spike potentiated by 8-Br-cAMP. For the 
second peak of Isc, none of the CysLTi antagonists reduced the response significantly. 
The summarized data is shown in Fig. 3.3.2.7 — 3.3.2.12. The data shows that the 8-
Br-cAMP-evoked cAMP signalling was affected by pranlukast and zafirlukast, but 
unlikely by montelukast. 
Forskolin and 8-Br-cAMP are general cAMP level elevators, which cannot 
distinguish between their two downstream targets, PKA and Epac. 8-CPT-2'-0-Me-
cAMP and Sp-6-Phe-cAMPs were thus employed to potentiate the UDP-induced Isc. 
It is noted that Sp-6-Phe-cAMPs activates PKA but not Epac, and thus serves as a 
negative control of Epac. 8-CPT-2'-0-Me-cAMP and Sp-6-Phe-cAMPs were added 
10 minutes before the addition of UDP to the epithelia. Both the first and second peak 
of Isc responses were analyzed. 8-CPT-2‘-0-Me-cAMP, the Epac activator, 
potentiated the first peak of Isc to 140.25 土 7.2 % (Isc potentiated from 17.50 ± 1.95 
jxA/cm^ to 24.54 士 1.26 p<0.05, n = 4-6), but the second peak was not 
significantly potentiated. With the co-incubation of CysLTi antagonists, it was found 
that only pranlukast significantly reduced the first Isc peak response to 33.55 士 9.62 % 
(Isc reduced from 24.54 士 1.26 ^lA/cm" to 8.23 士 0.63 |iA/cm^ p<0.01, n = 4-6). The 
second peak of Isc was not measured since 8-CPT-2‘ -O-Me-cAMP alone failed to 
potentiate the response. Fig. 3.3.2.13 - 3.3.2.17 shows the summarized data. From the 
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data, it appears that only pranlukast could reduce the Isc response potentiated through 
the action of Epac. 
Sp-6-Phe-cAMP, which activates PKA but not Epac, was employed to further 
elucidate the signalling mechanism involved. Same as 8-CPT-2‘-O-Me-cAMP, Sp-6-
Phe-cAMP potentiated the first peak of Isc, but not the second peak. The first peak of 
Isc, raised to 128.10 士 6.55 % of the control response (Isc potentiated from 17.50 士 
1.95 loA/cm- to 22.42 土 1.15 [lA/cm-, p<0.05, n = 4-6). Of the three CysLT, 
antagonists, only zafirlukast inhibited the first peak of Isc, to 70.30 士 4.20 % (Isc 
reduced from 22.42 士 1.15 ^lA/cm^ to 15.76 士 1.40 ]xA/cm', p<0.05, n = 4-6). There 
was no significant inhibition of first Isc peak by montelukast or pranlukast. Data is 
shown in Fig. 3.3.2.18 - 3.3.2.22. From the data, zafirlukast may inhibit the Isc 
response by acting through PKA. 
The cAMP-dependent pathway underlying the effect of montelukast, 
pranlukast and zafirlukast to UDP was also studied by PKA activity assay. PKA 
activity in 16HBE14o- was measured by a PKA assay that measures the 
phosphorylation of Kemptide, a synthetic substrate specific for PKA. The PKA 
activity was measured as a function of fluorescence intensity. As shown in Fig. 
3.3.2.23 A, phosphorylated peptide migrated towards the positively charged anode. 
Application of 100 \iM UDP for 5 minutes significantly increased the PKA activity by 
150 士 20.20 % (PKA activity increased from 3.0 x lO? 士 4 x 10^  units to 4.5 x 10? 士 5 
X 10^ units, p<0.05, n = 4) when compared with cells without any treatment. The 
UDP-induced PKA activity was suppressed under the pre-treatment of zafirlukast to 
82 士 15.10 %; (PKA activity decreased from 4.5 x 10? 士 5 x 10^ units to 3.7 x lO? 士 4 
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X 10^ units, p<0.05, n = 4) whereas montelukast and pranlukast could not 
significantly inhibit the UDP-induced PKA activity. Summarized data is shown in 
Fig. 3.3.2.23 B. 
Taken together, pranlukast may inhibit the cAMP-dependent pathway by 
acting through Epac, whilst zafirlukast is likely to inhibit the cAMP-dependent 
pathway by acting through PKA. Montelukast, however, does not exert similar 
inhibitory action in the cAMP-dependent pathway. 
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Figure 3.3.2.1 Representative recordings of Isc in response to the application of 100 
|J.M UDP, with or without forskolin. 16HBE14o- cells were initially bathed with 
normal KH solution. The KH solution was then changed to a KH solution with 
reduced CP concentration. Control cells were stimulated with the application of 100 
UDP alone (n = 4). Treated cells were pre-treated with 1 |xM forskolin 10 minutes 
prior to the application of 100 |xM UDP (n = 4-6). The additions of UDP and forskolin 
are shown by the arrows. 
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Figure 3.3.2.2 Effect of potentiating the epithelia with forskolin on first Isc peak in 
response to the application of 100 |iM UDP in a KH solution with reduced CI" 
concentration. 16HBE14o- cells were pre-treated with 1 )iM forskolin prior to the 
application of 100 \xM UDP (n = 4-6). Control was the application of 100 \iU UDP 
alone (n = 4). Each column represents the mean 士 S.E. Statistical difference between 
the treated groups and control is indicated by **P < 0.01 (Student /-test). 
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Figure 3.3.2.3 Effect of potentiating the epithelia with forskolin on second “c peak in 
response to the application of 100 |iM UDP in a KH solution with reduced CI" 
concentration. 16HBE14o- cells were pre-treated with 1 jiM forskolin prior to the 
application of 100 \iM UDP (n = 4-6). Control was the application of 100 |iM UDP 
alone (n = 4). Each column represents the mean 士 S.E. Statistical difference between 
the treated groups and control is indicated by *P < 0.05 (Student /-test). 
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Figure 3.3.2.4 Representative recordings of Isc in response to the application of 100 
I^ M UDP, with or without co-incubation of CysLTi antagonists and forskolin. 
16HBE140- cells were initially bathed with normal KH solution. The KH solution 
was then changed to a KH solution with reduced CI" concentration. Control cells were 
pre-treated with 1 |iM forskolin 10 minutes prior to the application of 100 |xM UDP (n 
=4 -6 ) . Treated cells were co-incubated with 1 |iM forskolin and 1 |aM CysLTi 
antagonists 10 minutes prior to the application of 100 |iM UDP (n = 6). The additions 
of UDP, CysLTi antagonists and forskolin are shown by the arrows. 
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Figure 3.3.2.5 Effect of CysLTi antagonists and forskolin co-incubation on first Isc 
peak in response to the application of 100 |iM UDP in a KH solution with reduced CI" 
concentration. 16HBE14o- cells were pre-treated with 1 |xM CysLTi antagonists and 
1 |iM forskolin prior to the application of 100 |iM UDP (n = 5). Control cells were 
pre-treated with 1 \xM forskolin 10 minutes prior to the application of 100 |iM UDP (n 
=4-6) . Each column represents the mean 士 S.E. Statistical difference between the 
treated groups and control is indicated by *P < 0.05 and **P < 0.01 (Student Mest). 
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Figure 3.3.2.6 Effect of CysLTi antagonists and forskolin co-incubation on second Isc 
peak in response to the application of 100 |iM UDP in a KH solution with reduced CI" 
concentration. 16HBE14o- cells were pre-treated with 1 )iM CysLTi antagonists and 
1 |iM forskolin prior to the application of 100 i^M UDP (n = 5). Control cells were 
pre-treated of 1 |xM forskolin 10 minutes prior to the application of 100 |iM UDP (n = 
4-6). Each column represents the mean 士 S.E. No statistical difference between the 
pretreated groups and the control groups are observed (Student /-test). 
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Figure 3.3.2.7 Representative recordings of Isc in response to the application of 100 
jaM UDP, with or without pre-treatment of the epithelia with 8-Br-cAMP. 
16HBE140- cells were initially bathed with normal KH solution. The KH solution 
was then changed to a KH solution with reduced CI" concentration. Control cells were 
stimulated with the application of 100 |a.M UDP alone (n = 4). Treated cells were pre-
treated with 1 |j.M 8-Br-cAMP 10 minutes prior to the application of 100 |iM UDP (n 
=4-6). The additions of UDP and 8-Br-cAMP are shown by the arrows. 
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Figure 3.3.2.8 Effect of potentiating the epithelia with 8-Br-cAMP on first Isc peak in 
response to the application of 100 |xM UDP in a KH solution with reduced CI" 
concentration. 16HBE14o- cells were pre-treated with 1 |iM 8-Br-cAMP prior to the 
application of 100 \iM UDP (n = 4-6). Control was the application of 100 i^M UDP 
alone (n = 4). Each column represents the mean 士 S.E. Statistical difference between 
the treated groups and control is indicated by **P < 0.01 (Student /-test). 
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Figure 3.3.2.9 Effect of potentiating the epithelia with 8-Br-cAMP on second Isc peak 
in response to the application of 100 jiM UDP in a KH solution with reduced CI" 
concentration. 16HBE14o- cells were pre-treated with 1 |xM 8-Br-cAMP prior to the 
application of 100 [lM UDP (n = 4-6). Control was the application of 100 i^M UDP 
alone (n = 4). Each column represents the mean 士 S.E. Statistical difference between 
the treated groups and control is indicated by *P < 0.05 (Student /-test). 
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Figure 3.3.2.10 Representative recordings of Isc in response to the application of 100 
)xM UDP, in the absence or present of co-incubation with CysLTi antagonists and 8-
Br-cAMP. 16HBE140- cells were initially bathed with normal KH solution. The KH 
solution was then changed to a KH solution with reduced CP concentration. Control 
cells were pre-treated with 1 [iM 8-Br-cAMP 10 minutes prior to the application of 
100 |iM UDP (n = 4-6). Treated cells were co-incubated with 1 i^M 8-Br-cAMP and 1 
luiM CysLTi antagonists 10 minutes prior to the application of 100 |iM UDP (n = 6-7). 
The additions of UDP, CysLTi antagonists and 8-Br-cAMP are shown by the arrows. 
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Figure 3.3.2.11 Effect of CysLTi antagonists and 8-Br-cAMP co-incubation on first 
Isc peak in response to the application of 100 |liM UDP in a KH solution with reduced 
Cr concentration. 16HBE14o- cells were pre-treated with 1 jxM CysLTi antagonists 
and 1 }iM 8-Br-cAMP prior to the application of 100 \iM UDP (n = 5). Control was 
pre-treatment of the cells with 1 |j,M 8-Br-cAMP 10 minutes prior to the application 
of 100 |iM UDP (n = 4-6). Each column represents the mean 士 S.E. Statistical 
difference between the treated groups and control is indicated by < 0.05 and 
< 0.01 (Student Mest). 
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Figure 3.3.2.12 Effect of CysLTi antagonists and 8-Br-cAMP co-incubation on 
second Isc peak in response to the application of 100 |iM UDP in a KH solution with 
reduced CI" concentration. 16HBE14o- cells were pre-treated with 1 |xM CysLTi 
antagonists and 1 |xM 8-Br-cAMP prior to the application of 100 |iM UDP (n = 5). 
Control was pre-treatment of the cells with 1 |xM 8-Br-cAMP 10 minutes prior to the 
application of 100 |xM UDP (n = 4-6). Each column represents the mean 士 S.E. No 
statistical difference between the pretreated groups and the control groups are 
observed (Student Mest). 
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Figure 3.3.2.13 Representative recordings of Isc in response to the application of 100 
|iM UDP, with or without pre-treatment of the cells with 8-CPT-2'-0-Me-cAMP. 
16HBE14o- cells were initially bathed with normal KH solution. The KH solution 
was then changed to a KH solution with reduced CI" concentration. Control cells were 
stimulated with the application of 100 |iM UDP alone (n = 4). Treated cells were pre-
treated with 1 i^M 8-CPT-2'-0-Me-cAMP 10 minutes prior to the application of 100 
\iM UDP (n = 4-6). The additions of UDP and 8-CPT-2'-0-Me-cAMP are shown by 
the arrows. 
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Figure 3.3.2.14 Effect of potentiating the epithelia with 8-CPT-2，-0-Me-cAMP on 
first Isc peak in response to the application of 100 |LIM UDP in a KH solution with 
reduced CI" concentration. Treated cells were pre-treated with 1 [M 8-CPT-2'-0-Me-
cAMP prior to the application of 100 |iM UDP (n = 4-6). Control was the application 
of 100 jxM UDP alone (n = 4). Each column represents the mean 士 S.E. Statistical 
difference between the treated groups and control is indicated by *P < 0.05 (Student 
Mest). 
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Figure 3.3.2.15 Effect of potentiating the epithelia with 8-CPT-2'-0-Me-cAMP on 
second Isc peak in response to the application of 100 |iM UDP in a KH solution with 
reduced CI" concentration. Treaeted cells were pre-treated with 1 i^M 8-CPT-2'-0-
Me-cAMP prior to the application of 100 |xM UDP (n = 4-6). Control was the 
application of 100 |iM UDP alone (n = 4). Each column represents the mean 士 S.E. 
No statistical difference between the pretreated groups and the control groups are 
observed (Student Mest). 
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Figure 3.3.2.16 Representative recordings of Isc in response to the application of 100 
|xM UDP, with or without co-incubation of CysLTi antagonists and 8-CPT-2'-0-Me-
cAMP. 16HBE140- cells were initially bathed with normal KH solution. The KH 
solution was then changed to a KH solution with reduced CI" concentration. Control 
cells were pre-treated with 1 |xM 8-CPT-2'-0-Me-cAMP 10 minutes prior to the 
application of 100 [iM UDP (n = 4-6). Cells were co-incubated with 1 |xM 8-CPT-2'-
O-Me-cAMP and 1 [iM CysLTi antagonists 10 minutes prior to the application of 100 
|iM UDP (n = 6). The additions of UDP, CysLTi antagonists and 8-CPT-2'-0-Me-
cAMP are shown by the arrows. 
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Figure 3.3.2.17 Effect of CysLTi antagonists and 8-CPT-2'-0-Me-cAMP co-
incubation on first Isc peak in response to the application of 100 jxM UDP in a KH 
solution with reduced CI" concentration. 16HBE14o- cells were pre-treated with 1 jxM 
CysLT, antagonists and 1 i^M 8-CPT-2'-0-Me-cAMP prior to the application of 100 
i^M UDP (n = 5). Control was pre-treatment of 1 ^M8-CPT-2'-0-Me-cAMP 10 
minutes prior to the application of 100 jxM UDP (n = 4-6). Each column represents 
the mean 士 S.E. Statistical difference between the treated groups and control is 
indicated by **P < 0.01 (Student Mest). 
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Figure 3.3.2.18 Representative recordings of Isc in response to the application of 100 
|iM UDP in the absence or presence of Sp-6-Phe-cAMP. 16HBE14o- cells were 
initially bathed with normal KH solution. The KH solution was then changed to a KH 
solution with reduced CI" concentration. Control cells were stimulated with the 
application of 100 \iM UDP alone (n = 4). Treated cells were pre-treated with 1 )xM 
Sp-6-Phe-cAMP 10 minutes prior to the application of 100 pM UDP (n = 4-6). The 
additions of UDP and Sp-6-cAMP are shown by the arrows. 
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Figure 3.3.2.19 Effect of potentiating the epithelia with Sp-6-Phe-cAMP on first Isc 
peak in response to the application of 100 |j.M UDP in a KH solution with reduced CI" 
concentration. Treated cells were pre-treated with 1 ^M Sp-6-Phe-cAMP prior to the 
application of 100 i^M UDP (n = 4-6). Control was the application of 100 \ M UDP 
alone (n = 4). Each column represents the mean 土 S.E. Statistical difference between 
the treated groups and control is indicated by *P < 0.05 (Student /-test). 
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Figure 3.3.2.20 Effect of potentiating the epithelia with Sp-6-Phe-cAMP on second 
Isc peak in response to the application of 100 |iM UDP in a KH solution with reduced 
Cr concentration. Treated cells were pre-treated with 1 |xM Sp-6-Phe-cAMP prior to 
the application of 100 \iM UDP (n = 4-6). Control was the application of 100 [M 
UDP alone (n = 4). Each column represents the mean 士 S.E. Statistical difference 
between the treated groups and control is indicated by *P < 0.05 (Student Mest). 
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Figure 3.3.2.21 Representative recordings of Isc in response to the application of 100 
|iM UDP, with or without co-incubation of CysLTi antagonists and Sp-6-Phe-cAMP. 
16HBE140- cells were initially bathed with normal KH solution. The KH solution 
was then changed to a KH solution with reduced CI" concentration. Control cells were 
pre-treated with 1 |xM Sp-6-Phe-cAMP 10 minutes prior to the application of 100 |iM 
UDP (n = 4-6). Treated cells were co-incubated with 1 |xM Sp-6-Phe-cAMP and 1 \iM 
CysLTi antagonists 10 minutes prior to the application of 100 }iM UDP (n = 6). The 
additions of UDP, CysLTi antagonists and Sp-6-Phe-cAMP are shown by the arrows. 
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Figure 3.3.2.22 Effect of CysLTi antagonists and Sp-6-Phe-cAMP co-incubation on 
first Isc peak in response to the application of 100 [iM UDP in a KH solution with 
reduced CI" concentration. 16HBE14o- cells were pre-treated with 1 |iM CysLTi 
antagonists and 1 |xM Sp-6-Phe-cAMP prior to the application of 100 |xM UDP (n = 
5). Control was pre-treatment of the epithelia with 1 |iM Sp-6-Phe-cAMP 10 minutes 
prior to the application of 100 i^M UDP (n = 4-6). Each column represents the mean ± 
S.E. Statistical difference between the treated groups and control is indicated by **P 
< 0.05 (Student /-test). 
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Figure 3.3.2.23 Effect of montelukast, pranlukast and zafirlukast on UDP-evoked 
PKA activity. A: Confluent l6HBE14o- cells were stimulated with UDP for 5 
minutes with or without pre-treatment of the cells with montelukast, pranlukast or 
zafirlukast. The PKA activity was measured as a function of fluorescence intensity. B: 
Summarized data showing the relative fluorescence intensity of various treatments. 
Each column represents the mean 士 S.E. Statistical difference between the treated 
groups and control is indicated by < 0.05 (Student Mest). 
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3.4 Effects of montelukast, pranlukast and zafirlukast on other P2Y receptor 
agonists on 16HBE14o- cells 
Besides P2Y6 receptors, 16HBE14o- cells express other P2Y family subtypes, 
namely P2Yi, P2Y2 and P2Y4, which also regulate ion transport in the epithelia 
(Communi et al., 1999; Wolff et al, 2005). In the present study, the effects of 
montelukast, pranlukast and zafirlukast to other P2Y receptor subtypes agonists on Isc 
were measured. 2-Me-S-ADP is the specific agonists of P2Yi receptor (Tulapurkar et 
al., 2004), and UTP is the specific agonists of both P2Y2 and P2Y4 receptors 
(Lazarowski et al” 2001). 
3.4.1 Effects of montelukast, pranlukast and zafirlukast on 2-methio-ADP-
induced Isc and [Ca^ J^i responses on 16HBE14o- cells 
P2Yi receptor is responsible for platelet aggregation. By binding with 2-
methio-ADP, the specific agonists of P2Yi receptor, it triggers the mobilization of 
intracellular calcium via activation of phospholipase C (Gachet et al., 2001). In the 
present study, the application of 100 jiM 2-Me-S-ADP did not elicit any discernible 
increase in “c and [Ca'^Ji responses. In spite of its presence in 16HBE14o- cells, P2Yi 
may not exert any stimulatory effect in this cell line. Thus, the effects of all three 
CysLT] receptor antagonists cannot be studied. Fig. 3.4.1.1 showed the representative 
recordings of Isc and [Ca'^]i. 
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Figure 3.4.1.1 Representative recording of Isc and [Ca~ ]^i in response to the 
application of 100 |iM 2-Me-S-ADP (n = 4). A: 16HBE14o- cells were initially 
bathed with normal KH solution. The KH solution was then changed to a KH solution 
with reduced CP concentration. Cells were stimulated with the apical application of 
100 |iM 2-Me-S-ADP (n = 4). B: 16HBE14o- cells were initially perfused with 
normal KH solution. The KH solution was then changed to a free KH solution. 
Cells were stimulated with the application of 100 \iM 2-Me-S-ADP (n = 4). 
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3.4.2 Effects of montelukast, pranlukast and zafirlukast on UTP-induced he and 
[Ca2+Ji responses on 16HBE14o- cells 
P2Y2 and P2Y4 receptors are membrane-bound receptors that mediate the 
actions of extracellular nucleotides in cell-to-cell signalling. Coupling of UTP to these 
two receptors results in the activation of phospholipase C and thus increases the 
intracellular Ca"^ (Lazarowski et aL, 2001). 
UTP causes a rise in both Isc and ]i response. Apical application of 100 
|iM UTP induced a rise in Isc response, and subsequently followed by a progressive 
decrease in Isc below the former baseline value. Under the pre-treatment of 
montelukast, pranlukast and zafirlukast, the UTP-induced Isc increase remained 
unchanged. Summarized data is shown in Fig. 3.4.1.1 - 3.4.1.2. The decrease in Isc 
following the first Isc response was also measured. The decrease in Isc below initial 
values were significantly larger in the presence of pranluakast (Isc decreased from -
12.23 士 1.23 |iA/cm- to -35.23 士 5.22 p<0.01, n = 4-6) or zafirlukast (Isc 
dropped from -12.23 士 1.23 ^lA/cm' to -22.41 士 2.30 ^lA/cm^ p<0.05, n = 4-6)， 
respectively. The data indicated that pranlukast and zafirlukast may be involved in the 
decrease in Isc activated by UTP. However, the detailed mechanism remains 
unresolved. 
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Figure 3.4.2.1 Representative recordings of Isc and in response to the 
application of 100 [M UTP, in the absence or presence of montelukast, pranlukast 
and zafirlukast. A: 16HBE14o- cells were initially bathed with normal KH solution. 
The KH solution was then changed to a KH solution with reduced CI" concentration. 
16HBE140- cells were pre-treated with or without 1 [xM montelukast, pranlukast or 
zafirlukast 10 minutes prior to the application of 100 |iM UTP (n = 4-6). B: 
16HBE140- cells were initially perfused with normal KH solution. The KH solution 
was then changed to a KH solution with Ca"^ free KH concentration. 16HBE14o-
cells were pre-treated with or without 1 \M montelukast, pranlukast or zafirlukast 10 
minutes prior to the application of 100 |iM UTP (n = 5). 
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Figure 3.4.3.2 Effect of montelukast, pranlukast and zafirlukast on Isc in response to 
the application of 100 |iM UTP in a KH solution with reduced CI" concentration. 
16HBE14o- cells were pre-treated with 1 jiM montelukast prior to the application of 
100 \LM UDP (n = 5). Control was the apical application of 100 |iM UTP without pre-
treatment (n = 4-6). Each column represents the mean 士 S.E. No significance between 
the control and pretreated groups is observed (Student /-test). 
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Figure 3.4.3.3 Effect of montelukast, pranlukast and zafirlukast on Isc in response to 
the application of 100 |iM UTP in a Ca"^ free KH solution. 16HBE14o- cells were 
pre-treated with 1 |iM montelukast prior to the application of 100 jiM UDP (n = 5). 
Control was the application of 100 jiM UTP without pre-treatment (n = 4-6). Each 
column represents the mean 士 S.E. No significance between the control and pretreated 




4.1 Differential effects of CysLTi antagonists to P2Y6 agonist on Isc and in 
16HBE140- cells 
Human airway epithelium is covered by airway surface liquid (ASL). To 
maintain normal airway functions, proper thickness and composition of ASL are 
essential. This is regulated by the absorptive and secretory functions of ions and water 
in the airway epithelium. Previous studies have addressed that the regulation of ion 
transport in human airway epithelial cells depends greatly on P2Y receptors, which 
are expressed in apical and/or basolateral cell membranes (Paradiso et aL, 1995; 
Bucheimer & Linden 2004). Among all P2Y receptor subtypes, P2Y6 receptor 
contributes specifically in the inflammatory processes (Cox et al” 2005). Recently, it 
has been discovered that cross-talks exist between P2Y6 and CysLTi receptors 
(Mellor et al.’ 2001; Mamedova et aL, 2005). CysLTi is the receptor of cysteinyl 
leukotrienes, which are key mediators of airway inflammatory disorders. Both P2Y 
and CysLTi receptors belong to the superfamily of GPCRs. Previous studies have 
proven the functional and structural similarities between these two receptors 
(Fredriksson et al., 2003; Gearing et al., 2003; Mamedova et al” 2005; Jiang et al, 
2009). The relationship between CysLTi and P2Y6 receptors has been emphasized in 
many studies because the distribution of these two receptors overlap in many 
inflammatory cells, such as leukocytes, eosinophil and blood monocytes (Mamedova 
et al., 2005; Ballerini et al” 2005). In the present study, the effects of three specific 
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CysLTi antagonists on nucleotides acting on P2Y6 receptor in 16HBE14o- cells were 
examined. 
Firstly, the presence of P2Y6 and CysLTi receptors in the 16HBE14o- cells 
was examined. P2Y6 (Communi et al” 1999) and CysLTi (Brink et aL, 2003; Profita 
et al., 2008) receptors were found to be present in the human bronchial epithelial cells. 
This is consistent with our data, demonstrating the presence of P2Y6 and CysLTi 
receptors in the 16HBE14o- cells by western blotting technique (Fig 3.1.1 - 3.1.2). 
The effects of CysLTi antagonists on P2Y6 receptor-mediated ion transport 
process and calcium signalling were investigated by short-circuit current (Isc) 
technique and intracellular calcium measurement. The measurement of Isc is 
an index of electrogenic ion transport across cell membranes. The setup comprises of 
a conventional Ussing chamber, in which cell monolayers grown on permeable filters 
would be mounted between two half-chambers. Transepithelial voltage is generated 
when ions transport across the epithelia. The transepithelial potential between the 
apical and basolateral side of the cells is kept at zero mV by external current. The 
amount of current applied is Isc. An upward Isc deflection indicates the net movement 
of anions from basolateral to apical compartment or net movement of cations from 
apical to basolateral compartment. Electroneutral ion transport would not be measured 
in this set up since it does not alter transepithelial potential. In addition, paracellular 
movement of ions driven by electrostatic attractive force is prevented because the cell 
layer is clamped at zero mV. Thus, Isc has been regarded as a powerful yet simple tool 
to study electrogenic ion transport across tissue layers. For [Ca' ]i measurement, cells 
grown on glass coverslips would be loaded with Ca^'^-sensitive dye, Fura-2-AM and 
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mounted in a miniature chamber. The change of [Ca^^l could be monitored and the 
calcium images are captured by the CCD camera for further analysis. Thus, a 
continual measurement of [Ca2+]i with live calcium images can be performed. This 
microspectrofluorometric technique greatly facilitates the study of intracellular 
calcium signalling. 
In this study of Isc, UDP, the specific agonist of P2Y6 receptor, was applied to 
both apical and basolateral sides of the cells. In the experiments, the epithelia were 
bathed in asymmetric KH solution so as to apply a basolateral to apical CI" gradient. 
Previous studies showed that amiloride, the blocker of the epithelial sodium channel 
(ENaC), failed to alter basal Isc in 16HBE14o- cells (Bernard et al.’ 2003), indicating 
that sodium reabsorption is not present in this cell line. Therefore, the increase in Isc 
would be due to CI" secretion. Addition of UDP to the apical side of 16HBE14o-
rapidly increased Isc in a concentration dependent manner (Fig 3.2.1.1 一 3.2.1.3). The 
Isc change consisted of biphasic responses, namely an initial transient peak (first peak) 
and a second rise peak (second peak) within 5 minutes. Previous studies also reported 
a biphasic response of UDP (Chan et al., 2000). It has been suggested that the first 
peak is due to the instant membrane depolarization and thus the transport of CI" ions. 
The second peak is sustained by the mobilization of Ca^^ ions from intracellular store. 
On the contrary, the addition of basolateral UDP evoked only a small and variable 
increase in Isc in both phases (Fig 3.2.1.1 - 3.2.1.3). The small Isc response induced by 
UDP may contribute to the fact that much less P2Y6 receptors are present in the 
basolateral side of the human bronchial epithelia (Wolff et al., 2005). Alternatively, it 
may be due to low signal transduction efficiency and thus inefficient coupling of 
basolateral P2Y6 receptor to Ca^^ signalling pathway. Due to the small response of 
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basolateral UDP-induced Isc, only Isc induced by apical addition of UDP would be 
investigated with CysLTi antagonists. For the study of cells loaded with Ca^^-
sensitive dye, Fura-2-AM, were perfused with normal KH solution. The normal KH 
solution containing 2.5 mM Ca^ "^  was then changed to Ca^^-free KH solution, which 
encourages the mobilization of intracellular Ca^ "^  store. Upon the application of UDP, 
[Ca2+]i increases in a concentration dependent manner (Fig. 3.2.1.4 - 3.2.1.5). 
The effects of three commonly used CysLTi antagonists, namely montelukast, 
pranlukast and zafirlukast, on UDP-induced Isc were examined. The specificity of 
them to CysLTi receptor is: montelukast > pranlukast > zafirlukast (Ravasi et al., 
2001). To examine the effect of the CysLTi antagonists on UDP-induced Isc, the cells 
were pretreated with CysLTi antagonists 10 minutes before addition of UDP. As 
mentioned above, the UDP-induced Isc response could be divided into two 
components, namely first and second peaks. In general, all three CysLTi antagonists 
inhibited the first peak of UDP-induced Isc, with montelukast causing the largest 
inhibition. However, the second Isc peak was not influenced by these antagonists 
(Montelukast: Fig.3.2.2.1 - 3.2.2.6; Pranlukast: Fig. 3.2.3.1 - 3.2.3.5; Zafirlukast: Fig. 
3.2.4.1 一 3.2.4.5). Our data is consistent with previous studies showing that CysLTi 
antagonists functionally interact with the signaling pathway of purinergic 2Y 
receptors (Mamedova et al., 2005; Capra et al., 2005). The discrepancy of the effects 
of CysLTi antagonists to the first and second peaks of the UDP-induced Isc requires 
further investigation. For the measurement, only montelukast showed an 
inhibition of the UDP-evoked increase, indicating that montelukast interferes 
with UDP-coupled calcium signalling pathway (Fig. 3.2.2.4 - 3.2.2.6). Mamedova et 
al also reported similar inhibition by montelukast in human monocyte-like cell line 
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(Mamedova et al., 2005). These findings bring our attention to the possible interaction 
between these two receptor families, which both belong to G-protein coupled receptor 
family. 
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4.2 Possible cellular mechanism(s) underlying the effects of CysLTi antagonists 
on UDP-induced increase in 16HBE14o- cells 
P2Y6 receptors have been shown to couple to two independent signalling 
pathways, causing a synergistic increase in cAMP and intracellular calcium (Kottgen 
et al.’ 2003). Recently, we have also demonstrated that P2Y6 receptors couple to both 
cAMP- and Ca^''-dependent pathways in 16HBE14o- cells (Wong et aL, 2009). For 
the Ca2+-dependent pathway, upon coupling of UDP to P2Y6 receptor, there is an 
elevation of which is caused by activation of PLC and thus an increased 
production of inositol trisphosphate (IP3) (Brunschweiger & Mueller et al., 2006). In 
our experiments, upon addition of UDP, there is a concentration-dependent increase 
in [Ca2+]i (Fig. 3.2.1.4 - 3.2.1.5). Unlike the biphasic Isc response, the UDP-induced 
[Ca2+]i response is monophasic. The difference in the UDP-induced Isc and [Ca^+Ji 
response patterns confirms that P2Y6 receptors couple to multiple pathways, probably 
to dual activations of Ca^^-dependent and Ca^ "^ - independent pathways as suggested in 
many studies (Son et al” 2004; Wong et al” 2009). 
As mentioned above, montelukast showed an inhibition to UDP-evoked 
[Ca""^ ]i increase, indicating that montelukast interferes with the UDP-induced calcium 
signalling pathway (Fig. 3.2.2.4 - 3.2.2.5). In contrast, pranlukast (Fig. 3.2.3.4 -
3.2.3.5) and zafirlukast (Fig. 3.2.4.4 - 3.2.4.5) did not cause any inhibition of the 
UDP-evoked increase, which rules out the possible involvement of these two 
CysLTi antagonists with the UDP-evoked calcium signalling. However, our data 
contradicts with the studies of Mamedova et al.’ reporting that pranlukast caused a 
concentration-dependent inhibition of change (Mamedova et al” 2005). 
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The cellular mechanism underlying the effect of montelukast was investigated 
in 16HBE140- cells treated acutely with drugs inhibiting the P2Y6-PLC-IP3-Ca2+-
signalling cascade at different levels. For the first series of experiments, the most 
downstream target, IP3 receptors, was inhibited by xestospongin C (XeC). XeC, a 
novel blocker of the IP3 receptor (Schaloske et al, 2000), reduced the UDP-induced 
[Ca2+]i increase (Fig. 3.3.1.1 - 3.3.1.2) However, co-incubation of XeC and 
montelukast did not cause an additional inhibition to UDP-induced increase 
when compared with the inhibition caused by montelukast alone (Fig. 3.3.1.3 -
3.3.1.5). Interestingly, the inhibition caused by co-incubation is less than that caused 
by montelukast alone. However, the underlying mechanism is yet investigated in the 
present study. The data suggests that montelukast may interfere with the pathway at a 
level upstream to IPs-induced Ca^^ release. U73122, a specific inhibitor of PLC, also 
reduced the UDP-induced increase (Fig. 3.3.1.6 - 3.3.1.7). Again, the co-
incubation of U73122 and montelukast failed to induce additional inhibition to UDP-
induced [Ca2+]i when compared with the inhibition caused by montelukast alone (Fig. 
3.3.1.8 - 3.3.1.10). Similar to XeC, the inhibition caused by the co-incubation is less 
than that by montelukast alone. The data rules out the possible interference of 
montelukast on the PLC activity. In short, montelukast is likely to interfere with the 
pathway at a level upstream to the PLC activity and the production of IP3, probably at 
the receptor level. 
At present, few studies have investigated the inhibitory mechanism of CysLTi 
antagonists on the UDP-induced response. Currently, there are mainly two 
suggestions regarding the possible inhibitory mechanism. Mellor et al suggests that 
montelukast may inhibit the UDP-induced Ca"^ response by desensitizing the P2Y6 
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receptors. Upon stimulation of its ligand, GPCR is activated, undergoes 
conformational change and couples to the heterotrimeric G proteins. However, the 
receptors may be desensitized meanwhile (Ferguson, 2001). There are mainly two 
types of desensitizations: homologous and heterologous (Chuang et al.’ 1996). In 
homologous desensitization, it is agonist-dependent, i.e. only activated receptors 
desensitize. No studies have reported that montelukast directly acts on P2Y6 receptor. 
Notably, Mellor et al. reported that CysLTi receptors in human cord-blood-derived 
human mast cells respond to UDP (Mellor et aL, 2001). On the other hand, in 
heterologous desensitization, activation of one receptor can result in reduced response 
to activation of other receptors that are not exposed to the agonist (Bunemann et al., 
1999). 
Recently, the most updated study by Jiang et al. states that CysLTi and P2Y6 
receptors have cross-regulation by coordinating their signalling events in a 
complementary sense at intracellular sites in mast cells (Jiang et al., 2009). In the 
study, the agonists of these two receptors, UDP and LTD4, both induced ERK 
phosphorylation and prolonged cell survival. However, the response of LTD4, the 
ligand of CysLTi receptor, was attenuated by the P2Y6 antagonist, MRS2578, which 
should not interfere with the effect of LTD4 on CysLTi receptor. In addition, Jiang et 
al. also shows that CysLTs desensitized the UDP stimulation in human mast cells. It 
appears that CysLTi and P2Y6 receptors cooperate with each other reciprocally. From 
our data, we demonstrate that CysLTi and P2Y6 receptors co-express in 16HBE Mo-
cells. However, our laboratory shows that LTD4, the most potent cysteinyl 
leukotriene (Lynch et al.’ 1999), failed to elicit Isc or response, suggesting that 
CysLTi receptors are not coupled to the Ca2+ signalling pathway and ion transport 
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activity (data not shown). Thus, the suggestion by Jiang et al may not be applicable 
in 16HBE140- cells. On the other hand, our study provides no solid proof for the 
receptor desensitization suggested by Mellor et al, 2005. Besides, our data shows that 
only montelukast applied at the apical but not basolateral compartment could inhibit 
the apical UDP-induced Isc. Together with the experiments performed in section 3.3, it 
is reasonable to suggest that montelukast directly inhibits P2Y6 receptors. Taken 
together, it is most likely that montelukast directly inhibits P2Y6 receptors and thus 
inhibits both Isc or responses. However, further experiments are necessary to 
confirm the hypothesis above. 
The change of intracellular calcium level depends on the mobilization of the 
intracellular store, as well as the influx of calcium from the external environment. 
Thus, the effect of montelukast on Ca^^ influx was also investigated. The cells were 
initially perfused with Ca^^ free KH solution. UDP was applied to stimulate C a � . 
release. Subsequently, the Ca2+ free KH solution was replaced by normal KH solution, 
containing 2.5 mM Ca^^. It induced an influx of Ca^^ to the cells. This protocol allows 
us to study the UDP-induced Ca^^ release and influx separately. Our data 
demonstrates that montelukast did not inhibit the Ca^^ influx component (Fig. 
3.3.1.11 - 3.3.1.12), ruling out its effect on Ca2+ entry. 
In summary, these findings imply that montelukast interferes with the Ca^^-
dependent pathway at a level above IP3 production and PLC activity, probably at the 
P2Y6 receptor level. By blocking the receptor, montelukast hence blocks the 
activation of PLC and IP3 production, thereby inhibiting the mobilization of Ca^^ from 
the internal store. 
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4.3 Possible cellular mechanism(s) underlying the effects of CysLTi antagonists 
on UDP-induced Isc in 16HBE14o- cells 
As mentioned in the previous section, UDP evidently stimulates cAMP 
production in addition to an increase in (Schreiber et aL, 2005; Wong et aL, 
2009). The cAMP production would in turn activate protein kinase A (PKA) and an 
Exchange protein directly activated by cAMP (Epac) (Rooij et al., 1998; Ster et aL, 
2007; Cheng et al,, 2008). 
To investigate the cellular mechanism induced by UDP that these three 
CysLT丨 antagonists may interfere with various drugs involving in the cAMP-
dependent pathway were applied. Similar experimental protocols were used as 
described in the previous section. Cells were treated with drugs activating the AC-
cAMP-PKA/Epac signalling cascade at different levels. Firstly, general cAMP level 
elevators, forskolin and 8-Br-cAMP, were used. Forskolin is an adenylyl cyclase 
activator and thus increases the intracellular level of cAMP (Lortet et al.’ 1999; 
Kopperud et al.，2003). The first and second peaks of Isc response were potentiated by 
forskolin (Fig. 3.3.2.1 - 3.3.2.3). Our data demonstrated that pranlukast and 
zafirlukast inhibited the first peak of the potentiated UDP-induced Isc. However, 
montelukast did not show any inhibition of the first peak of potentiated Isc (Fig. 
3.3.2.4 - 3.3.2.6). On the other hand, the second peak of the potentiated Isc was not 
inhibited by the three CysLTi antagonists (Fig. 3.3.2.4 - 3.3.2.6). Thus, the data 
shows that forskolin-cAMP signalling was affected by pranlukast and zafirlukast, but 
not by montelukast. 
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8-Br-cAMP, a cAMP analogue, was also applied to potentiate the UDP-
induced Isc. Similarly, the first and second peaks of UDP-induced Isc were potentiated 
(Fig. 3.3.2.7 - 3.3.2.9). Again, the first peak was inhibited by pranlukast and 
zafirlukast, but not montelukast. The second peak of UDP-induced Isc, on the other 
hand, was not influenced by the CysLTi antagonists (Fig. 3.3.2.10 - 3.3.2.12). The 
data is consistent with the conclusion drawn with the use of forskolin, showing that 
cAMP signalling evoked by either forskolin or 8-Br-cAMP was affected by 
pranlukast and zafirlukast, but unlikely by montelukast. 
As mentioned above, cAMP has two downstream targets, PKA and Epac, 
which cannot be distinguished by general cAMP level elevators. Thus, 8-CPT-2'-0-
Me-cAMP, the specific activator of Epac (Kang et al, 2003), was used to investigate 
the effect of CysLTi antagonists to Epac-potentiated Isc induced by UDP. 8-CPT-2'-
O-Me-cAMP potentiated the first peak, but not the second peak of the UDP-induced 
Isc (Fig. 3.3.2.13 - 3.3.2.15). The 8-CPT-2'-0-Me-cAMP-potentiated first peak of 
UDP-induced Isc was inhibited by pranlukast only (Fig. 3.3.2.16 - 3.3.2.17). It appears 
that pranlukast could reduce the Isc response potentiated through the action of Epac. 
There are two possibilities for the inhibitory mechanism. Pranlukast may inhibit the 
UDP-induced Isc through inhibition of cAMP production or Epac activation. However, 
it is unlikely that pranlukast inhibits the production of cAMP since pranlukast also 
inhibited the UDP-induced Isc potentiated by general cAMP analogue, 8-Br-cAMP. 
To confirm that pranlukast reduces the Isc response by acting through Epac, the 
technique of fluorescence resonance energy transfer (FRET) was employed (data not 
shown). In the study, we used a FRET-based cAMP indicator, CFP-Epac-YFP 
(Ponsioen et aL, 2004). 8-CPT-2‘-0-Me-cAMP activated Epac, which caused a 
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significant increase of FRET emission ratio. In the presence of pranlukast, 8-CPT-2'-
O-Me-cAMP failed to elicit an increase in FRET emission ratio, indicating that 
pranlukast inhibited the activated Epac. This data further confirms that pranlukast 
reduces UDP-evoked response by acting through the action of Epac. 
On the other hand, Sp-6-Phe-cAMP was served as an Epac-negative control 
because it activates PKA but not Epac (Li et al., 2007; Adamson et al., 2008). Sp-6-
Phe-cAMP also potentiated the first peak, but not the second peak of UDP-induced Isc 
(Fig. 3.3.2.18 - 3.3.2.20). The UDP-induced Isc first peak potentiated by Sp-6-cAMP 
was inhibited by zafirkast, but not montelukast or pranlukast (Fig. 3.3.2.21 - 3.3.2.22). 
From the data, zafirlukast may reduce the Isc response potentiated by PKA. 
The cAMP-dependent pathway underlying the effect of montelukast, 
pranlukast and zafirlukast to UDP was also studied by PKA activity assay. The data 
showed that UDP-induced PKA activity was suppressed only in the presence of 
zafirlukast (Fig. 3.3.2.23), confirming that zafirlukast could reduce the Isc response 
acting through the action of PKA. 
Taken together, these findings imply that montelukast, pranlukast and 
zafirlukast inhibited the Isc induced by apical application of UDP. In particular, 
pranlukast could inhibit the cAMP-dependent pathway potentiated through the action 
of Epac, whilst zafirlukast may inhibit the same pathway potentiated through PKA. 
Montelukast, however, does not interfere with the cAMP-dependent pathway at all. 
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4.4 Effects of CysLTi antagonists on other P2Y receptor subtypes in 16HBE14o-
cells 
Besides P2Y6 receptor, 16HBE14o- cells express other P2Y family subtypes, 
namely P2Yi, P2Y2 and P2Y4, which also regulate ion transport in the epithelia 
(Communi et al., 1999; Wolff et al., 2005). Our lab previously shows the expression 
of P2Yi, P2Y2 and P2Y4 and P2Y6 mRNA and protein expressions (Wong et aL, 
2009). Previous studies showed that CysLTi receptors antagonists interact with 
signalling pathway of purinergic 2Y receptor (Capra et aL, 2005). Thus, the effects of 
CysLTi antagonists on other P2Y receptors were investigated. 
2-Me-S-ADP, the P2Yi receptor agonist, was applied to evoke kc and 
2+ • * 
increase. However, no discernible increase of Isc and [Ca ]i could be detected in spite 
of the presence of P2Yi receptor in 16HBE14o- cells (Fig. 3.4.1.1). It contradicts the 
study by Mamedova et al. reporting that montelukast and pranlukast exhibited a 
concentration-dependent inhibition to 2-Me-S-ADP-induced change in 
DMSO-differentiated U937, a human monocyte-macrophage-like cell line 
(Mamedova et al” 2005). Thus, it is possible that the effect may be cell type specific. 
Although the investigation cannot be performed in this cell line, the possible 
interference of CysLTi antagonists to P2Yi receptor cannot be ruled out. 
P2Y2 and P2Y4 receptors were stimulated with their specific agonist, UTP. 
Addition of UTP induced a rise in Isc, and subsequently followed by a progressive 
decrease of Isc to below the baseline (Fig. 3.4.2.1 - 3.4.2.2). The pattern of UTP-
evoked Isc is consistent with study by Inglis et al’ stating that UTP evoked a 
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stimulatory phase and subsequently an inhibitory phase of Isc response (Inglis et aL, 
2000). It has been suggested that the inhibitory phase of the Isc response depends on 
the inhibition of epithelial Na+ channels (Ishikawa et aL, 1998) and transepithelial 
"Na+ absorption (Graham et al, 1992; Koster et ah, 1996). However, it is not possible 
in 16HBE14o- cells because Na+ absorption is not present in this cell line. 
Alternatively, Devor & Pilewski suggested that UTP may inhibit basolateral K+ 
channels in human bronchial epithelia (Devor & Pilewski, 1999), which is a sensible 
explanation since the basolateral K+ channel is well known for its involvement in the 
Cr transport in 16HBE14o- cells (Welsh, 1987; Willumsen et aL, 1989; Wong et aL, 
2009). From our data, the rise of Isc was not affected by montelukast, pranlukast or 
zafirlukast. In contrast, pranlukast and zafirlukast caused a larger drop of the 
progressive Isc decrease following the stimulatory phase of Isc (Fig. 3.4.2.2). We 
suggest that pranlukast and zafirlukast facilitate the inhibitory effect of UTP in the 
inhibitory phase, causing a greater inhibition of basolateral K+ channels and thus a 
larger and prolonged inhibition after the rise of UTP-induced Isc. However, to 
elucidate how pranlukast and zafirlukast facilitate the inhibitory effect of UTP in Isc, 
further investigation is necessary. On the other hand, montelukast failed to inhibit 
UTP-induced Isc. It is known that coupling of UTP to P2Y2 and P2Y4 receptors causes 
activation of PLC and an increase in intracellular calcium, which would also be 
activated by coupling of UDP to P2Y6 receptor. In spite of sharing the same signalling 
pathway, montelukast inhibits P2Y6 receptor-mediated pathway only, further 
supporting the notion that montelukast affects the UDP-evoked response at the 
receptor level. For the measurement, UTP also induced an increase in 
However, the UTP-induced change was not influenced by the presence of 
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CysLTi antagonists (Fig. 3.4.2.1 — 3.4.2.2), ruling out the interference of CysLTi 
antagonists in the Ca^^-dependent pathway of UTP-induced response. 
Taken together, addition of UTP causes a biphasic Isc response, comprised 
with a stimulatory phase followed by an inhibitory phase. Montelukast has no effect 
on both phases of the UTP-induced Isc response. Pranluakst and zafirlukast facilitate 
the inhibitory phase of UTP-induced Isc, probably by facilitating the inhibition of 
basolateral K+ channels. However, the detailed mechanism remains unresolved. 
Besides, the investigation of the CysLTi antagonists to P2Yi receptor is not feasible. 
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4.5 Summary: Possible Interaction between CysLTi antagonists and P2Y6 
receptor 
Overall, 16HBE14o- epithelia expresses CysLTi and at least four P2Y 
subtypes, namely P2Yi, P2Y2, P2Y4 and P2Y6 receptors. Recently, several studies 
reported that cross-talk exists between two receptors in the superfamily of GPCRs: 
CysLTi and P2Y6 receptors. The structural and functional similarities between these 
two receptors draw our attention to the possible cross-regulation and thus the fine 
adjustment of inflammatory processes they govern. From our studies, the CysLTi 
antagonists ~ montelukast, pranlukast and zafirlukast interfere the pathways of P2Y 
receptors differently. These three antagonists are from distinct chemical classes (Jones 
et al., 1989; Salvi et al, 2001) and are proven to have alleviating effect on the 
symptoms of airway disease, especially bronchial asthma and allergic rhinitis (Suissa 
et al.’ 1997; Capra et al.’ 2006; Riccioni et aL, 2007). 
Based on the current studies, we propose a model for the differential effects of 
CysLTi antagonists on UDP- and UTP-induced signalling pathways (Fig. 4.3.1). UDP 
binds to P2Y6 receptors and activates two signalling pathways. One of them is Ca� . -
dependent, causing the activation of PLC and production of IP3, resulting in an 
increase in Ca^^. The other pathway, which is Ca^^-independent, is the activation of 
AC, leading to a rise of cAMP, the second messager. cAMP in turn activates PKA and 
Epac. Both of them would potentiate CI" transport and possibly other related ion 
transport processes. All three CysLTi antagonists interfere the P2Y6 receptor-
mediated pathways separately. Montelukast inhibits the UDP-induced Isc and 
by acting on P2Y6 receptor itself. Pranlukast inhibits the UDP-induced Isc by 
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interfering the action of the downstream target of the Ca^^-independent signalling 
pathway, Epac. Zafirlukast inhibits the UDP-induced I s�by interfering the action of 
another downstream target of the Ca^^-independent signalling pathway, PKA. On the 
other hand, UTP activates P2Y2 and P2Y4 receptors, leading to an activation of PLC 
and thus the production of IP3. It causes an increase in intracellular calcium (Inglis et 
a!., 2000). From our data, addition of UTP causes an increase in Isc and 
However, pranlukast and zafirlukast inhibit Isc but not [Ca-^]i increase. For the Isc 
measurement, pranlukast and zafirlukast enhance the inhibitory phase of the UTP-
induced Isc in a mechanism yet fully explored. 
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Figure 4.5.1 A diagrammatic sketch showing the differential inhibition of the three 
CysLTi antagonists, namely montelukast, pranlukast and zafirlukast, on UDP- and 
UTP-induced Ca^^ and cAMP signalling pathways and ion transports in 16HBE Mo-
cells. 
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4.6 Clinical implications and perspectives 
Leukotrienes and their specific antagonists have been discovered for about 25 
years, the antagonists are now established as a new treatment of asthma and rhinitis. 
Previous studies have tested the antagonists both in vivo and in vitro in the animal and 
human tissues, from which their anti-inflammatory and bronchoprotective effects are 
proven (Capra et al., 2006). Currently, the antagonists are used as monotherapy or in 
combination with inhaled glucocorticosteroids or beta-agonists. In view of their anti-
inflammatory effect, Dahlen has proposed that treatment with antagonists should be 
tried in other disorders, such as food intolerance and atopic dermatitis (Dahlen, 2006). 
However, the exploration on this new class of drugs has just begun. The implications 
of our findings reveal that the use of the CysLTi antagonists may inhibit the signalling 
pathways of P2Y receptors for extracellular nucleotide, causing the fine adjustment of 
the inflammation processes and related actions. This may inspire a new combination 
of drug treatment to various types of inflammation. However, further studies should 
be prompted to judge the efficiency and the underlying cellular mechanisms for the 
therapeutic rationale. With respect to this study, the detail action mechanisms of 
CysLTi antagonists to inflammation-related P2Y receptors should be further 
investigated, in order to uncover the cross-regulatory mechanisms between CysLTi 
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